

(19) **DANMARK**

(10) **DK/EP 3169334 T3**



(12) **Oversættelse af  
europæisk patentskrift**

Patent- og  
Varemærkestyrelsen

- 
- (51) Int.Cl.: **A 61 K 38/18 (2006.01)**                      **A 61 K 31/7105 (2006.01)**                      **A 61 P 19/02 (2006.01)**  
**A 61 P 19/04 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2021-07-05**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2021-04-28**
- (86) Europæisk ansøgning nr.: **15747397.6**
- (86) Europæisk indleveringsdag: **2015-07-16**
- (87) Den europæiske ansøgnings publiceringsdag: **2017-05-24**
- (86) International ansøgning nr.: **EP2015066329**
- (87) Internationalt publikationsnr.: **WO2016009000**
- (30) Prioritet: **2014-07-16 EP 14177302**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Ethris GmbH, Semmelweisstrasse 3, 82152 Planegg, Tyskland**
- (72) Opfinder: **HASENPUSCH, Günther, Watzmannstrasse 5, 81541 München, Tyskland**  
**RUDOLPH, Carsten, Ringweg 4, 82152 Krailling, Tyskland**
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **RNA TIL ANVENDELSE TIL BEHANDLING AF LEDBÅNDS- ELLER SENELÆSIONER**
- (56) Fremdragne publikationer:  
**WO-A2-2007/103787**  
**US-A1- 2008 261 888**  
**US-A1- 2008 267 873**  
**RUAN HONGJIANG ET AL: "Prevention of Tendon Adhesions by ERK2 Small Interfering RNAs", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2013, vol. 14, no. 2, 2013, pages 4361-4371, XP002731230, ISSN: 1422-0067**  
**OZEKI NOBUTAKE ET AL: "Transplantation of Achilles tendon treated with bone morphogenetic protein 7 promotes meniscus regeneration in a rat model of massive meniscal defect", ARTHRITIS AND RHEUMATISM NOV 2013, vol. 65, no. 11, November 2013 (2013-11), pages 2876-2886, XP002745145, ISSN: 1529-0131**



## DESCRIPTION

**[0001]** The present invention relates to a liquid composition containing naked mRNA encoding a polypeptide as defined in the claims for use in the treatment or prevention of ligament or tendon lesions, wherein said RNA is solved in a glucose solution. Also disclosed herein is a method for treating ligament or tendon lesions comprising the administration of a liquid composition containing naked RNA, such as mRNA encoding a polypeptide which is beneficial in the process of healing the ligament or tendon lesions.

**[0002]** Ligaments are dense fibrous tissue structures composed primarily of highly oriented and tightly packed collagen fibrils. Due to this specialized matrix organization, ligaments possess large tensile strength and flexibility. At the same time, ligament injuries are one of the most common injuries to joints. Tendons have a crucial role in maintaining the body mechanics, as their main function is to connect muscles to bones. They are axial connective tissues that ensure transmission of the traction exerted by muscle to bone resulting in joint movements. Tendons are composed of a few cells and parallel arrays of collagen fibers. Their important mechanical function renders them liable to injury and rupture. Such injuries can be caused by different origins, such as trauma, overuse, consequence of metabolic disease or age-related loss of elasticity. Normally, ligaments and tendon may heal spontaneously but their regeneration is very difficult and requires a very long period, i.e. several months and sometimes even a year. Although the natural healing or an efficient surgical repair mostly permits restoration of satisfactory function, it often fails to restore the complete biological and biomechanical characteristics of an uninjured tissue. The healed ligament or tendon remains mechanically weak and susceptible to re-injury. Other lesions like tendinosis feature degenerative changes where all components of the tendon are affected (tenocytes, extracellular matrix and collagen). Where natural healing is insufficient, many of the ligament or tendon lesions continue to present clinical problems defying medical and surgical treatments. The failure to obtain optimal healing conditions led to new approaches taking into consideration advances in the comprehension of the ligament's or tendon's healing process at the cellular and molecular level. In the case of tendon healing this healing process consists of successive phases: clot formation, inflammation, proliferation, remodeling and maturation (Frank, CB, J. Am. Acad. Orthop. Surgeons 4 (1996), 74-83). Several growth factors and cytokines have been shown to play a role in the tendon repair process (Evans, CH, Sports Med. 28 (1999), 71-76). They act on vascular growth, cell migration, cell proliferation as well as collagen and extracellular protein synthesis. In order to optimize the healing process of ligament or tendon lesions, different approaches have been developed in order to deliver growth factors locally, in particular via gene transfer. Nakamura et al. (J. Clin. Invest. 97 (1996), 226-231) describes the transient introduction of a plasmid carrying a reporter gene ( $\beta$ -gal) into the healing rat patellar ligament so as to study the ligament's biology. The introduction of the plasmid DNA was achieved by using hemagglutinating virus of Japan (HVJ)-liposome mediated gene transfer. The same group reported subsequently that they had been able to introduce with the same technique a plasmid encoding platelet-derived growth factor (PDGF)-B into healing patellar ligament (Nakamura et al., Gene Therapy 5 (1998), 1165-1170). The liposome suspension was

injected directly into the injured patellar ligament of rats and an enhanced expression of PDGF-B in healing ligament could be observed up to 4 weeks after transfection leading to an initial promotion of angiogenesis and subsequent enhanced collagen deposition. Ozkan et al. (Eur. J. Clin. Invest. 29 (1999), 63-67) describes the direct in vivo gene transfer of a plasmid DNA containing the reporter gene  $\beta$ -gal into healing patellar ligament by intra-arterial delivery of HVJ-liposomes. In 2000, Goomer et al. (Clinical Orthopaedics and Related Research 379S (2000), S189-S200) reported on a non-viral in vivo gene transfer method for introducing plasmid DNA containing the  $\beta$ -gal, TGF- $\beta$ 1 or PTHrP gene into cartilage or tendon tissue. Jayankura et al. (J. Gene Med. 5 (2003), 618-624) report on in situ gene transfer into animal tendons by injection of naked DNA and electrotransfer. Gene expression was exclusively observed in cells adjacent to the injection site and along the needle track, indicating that the plasmid could not diffuse through the dense tendon and that the transduced cells do not migrate over time. Another non-viral delivery method of plasmid DNA to tendon tissue was reported by Delalande et al. (Ultrasonics 50 (2010), 269-272 and J. Controlled Release 156 (2011), 223-230). The authors introduced a plasmid encoding luciferase or human fibromodulin into tendon tissue of mice using microbubbles and ultrasound-assisted gene transfer. Suwalski et al. (Biomaterials 31 (2010), 5237-5245) describes the possibility to accelerate Achilles tendon healing by introducing a plasmid encoding PDGF via mesoporous silica nanoparticles. A further approach was described in Qui et al. (Gene Therapy 19 (2012), 703-710) using ultrasound-targeted microbubble destruction in order to enhance naked plasmid DNA transfection in rabbit Achilles tendons in vivo. WO 2007/103787 discloses the treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation. For example, in the context of WO 2017/103787, an interfering RNA molecule is to be used as a respective inhibitor and the inhibitor may be directly injected into the injured tendon tissue. In view of the intended use of gene therapy approaches in the context of healing lesions of ligaments and tendons in the clinic, it would be desirable to have at hand methods for applying the desired proteins in the form of nucleic acids which allow an easy handling.

**[0003]** The present application addresses this need by providing the embodiments as defined in the claims.

**[0004]** In particular, the present inventors have surprisingly found that it is possible to effectively deliver and express RNA, in particular mRNA encoding a polypeptide, to ligament or tendon tissue thereby allowing the expression of the desired polypeptide in the ligament or tendon tissue. The RNA is present in naked form in a liquid composition. This liquid composition can be delivered directly into ligament or tendon tissue, e.g. by injection, and there is no need for any gene transfer vectors or carriers for the RNA or methods for enhancing the transfer into the tissue like electrotransfer or ultrasound. Accordingly, the present invention allows for an easy way to deliver proteins by way of gene therapy via mRNA to ligament or tendon tissue which can be effectively implement in the clinic. Moreover, it was observed that expression of a protein encoded by an injected RNA is not only observed directly at the site of injection but also at more distant locations in the tendon. More particular, the injection of naked RNA, in particular naked chemically modified mRNA (cmRNA), in glucose-containing solution into tendons was shown to result in high protein expression in healthy and (experimentally)

injured tendons. For example, the injection of BMP-7 encoding cmRNA was shown to result in increased BMP-7 protein expression, less fulminant degradation of collagen type I, decreased collagen type III formation as well as trends towards higher collagen I/III ratio and chemotactic cell attraction in surgically dissected tendons. Furthermore, it was found that overexpression of BMP-7 especially during the inflammatory phase of tendon regeneration positively influences healing.

**[0005]** In comparison to DNA, RNA has the advantage that it prevents the risk of insertional mutagenesis and, consequently, genotoxicity. Moreover, the RNA, in particular cmRNA, to be employed in the context of the invention was shown to have excellent biological compatibility *in vivo* when injected locally into ligaments or tendons. For example, it was shown in the context of the invention that injection of RNA, in particular cmRNA, into either intact or injured tendons resulted in local and distinct protein expression. The respectively expressed proteins were biologically functional.

**[0006]** Thus, the present invention relates to a liquid composition containing naked RNA as defined in the claims for use in the treatment or prevention of ligament or tendon lesions (in a patient), wherein said RNA is solved in a glucose solution. It is particularly envisaged that the liquid composition of the invention is a liquid pharmaceutical composition.

The appended Examples show that it is possible to efficiently express proteins from mRNA in tendon tissue according to the present invention. However, the present disclosure is not restricted to the use of an RNA encoding a polypeptide. In the context of the present disclosure it is also possible to employ other kinds of RNA molecules, e.g. noncoding RNA, as will be explained further below.

**[0007]** A ligament is the fibrous tissue that connects bones to other bones and is also known as articular ligament, articular larua, fibrous ligament, or true ligament. Thus, the term "ligament" refers to a band of tough, fibrous dense regular connective tissue bundles, made of attenuated collagenous fibers; with said bundles protected by dense irregular connective tissue sheaths. Ligaments connect bones to other bones in order to stabilize joints. They do not connect muscles to bones; which is the function of tendons. Some ligaments limit the mobility of articulations, or prevent certain movements altogether.

**[0008]** The term "tendon" (or sinex) refers to a tough band of fibrous connective tissue that usually connects muscle to bone and is capable of withstanding tension. Tendons and muscles work together to move bones.

The term "lesion" refers to any kind of damage to the ligament or tendon which has a negative effect on its function, in particular a decrease in resilience, fracture toughness and/or tensile strength. A lesion can, e.g., be tissue inflammation with or without necrotic areas due to overuse, degeneration, a disease state, the cause of age, such as an age-related loss of function or elasticity, of an injury or a rupture. Moreover surgically dissected healthy tendons and ligaments which are proposed to be used as autologous or allogenic transplants for reconstructing diseased or ruptured tendons and ligaments are as well considered as lesioned, though a lesion-like state is generated as a consequence to the surgical procedure. It is, in

principle, envisaged in the context of the invention to treat (or prevent) any ligament or tendon injury or damage, any (degenerative) ligament or tendon disease or disorder and any (degenerative) ligamentopathy and (degenerative) tendinopathy.

**[0009]** In principle, a ligament or tendon lesion, a ligament or tendon injury or damage, a (degenerative) ligament or tendon disease or disorder or (degenerative) ligamentopathy and (degenerative) tendinopathy can develop in any tendon and ligament, respectively, of the body.

**[0010]** In a specific aspect, there is the problem that the healing/regeneration rate in the tendon/ligament is less than the injury/overload rate. In other words, there may be a tendon/ligament disrepair due to repetitive overloading. This leads to degeneration processes in the tendon/ligament. As such, tendinopathy/ligamentopathy is progressively worsening with the continued (over)use (of the affected joint/muscle(s)). Lateral epicondylitis, also known as lateral epicondylitis and "tennis elbow", respectively, is a common example of such a tendinopathy. It is characterized by lateral elbow pain caused by overuse. It affects about two percent of the population, mainly in the fourth and fifth decades. From a pathomechanical perspective, the forearm muscles and tendons become damaged from overuse, e.g. through repeating the same motions again and again. Furthermore, also intrinsic factors are associated with the risk of suffering from (degenerative) tendinopathy/ligamentopathy. These factors are factors like age, sex, obesity, and/or type II diabetes mellitus (Ribbans, Bone Joint J. 95-B, 2013, 305-313). While muscle fibers have high healing potential, ligament/tendon fibers are relatively avascular, less well supported by blood and tend to heal only very slowly. As a consequence, there may be a progressive inflammation (due to overuse); in case of the lateral epicondylitis, progressive inflammation of the tendons that join the forearm muscles on the outside of the elbow. The tendon usually involved in lateral epicondylitis is called *Extensor Carpi Radialis Brevis*.

**[0011]** The most common short term therapy for lateral epicondylitis is the injection of antiinflammatory drugs such as corticosteroids into the soft tissue surrounding the elbow. Although studies support their efficacy for short-term pain relief, they do not demonstrate long term benefit or healing. In another injection therapy autologous blood or platelet-rich plasma is injected. However, also these injection therapies do not show better efficacy over time than corticosteroid therapy.

**[0012]** It is clear from the above that there is also the need of prophylaxis and prevention, respectively, of a ligament or tendon lesion, a ligament or tendon injury or damage, a (degenerative) ligament or tendon disease or disorder or (degenerative) ligamentopathy and (degenerative) tendinopathy like, for example, lateral epicondylitis. Hence, in one embodiment, the present invention provides for such a prophylaxis and prevention, respectively, like, for example, prophylaxis/prevention of lateral epicondylitis. In particular, the present invention provides for the liquid composition containing naked RNA of the invention for use in preventing a ligament or tendon lesion, a ligament or tendon injury or damage, a (degenerative) ligament or tendon disease or disorder or (degenerative) ligamentopathy and (degenerative) tendinopathy. What has been said herein elsewhere with respect to the mode of

administration applies here, *mutatis mutandis*. In particular, it is envisaged that the liquid composition containing naked RNA to be used in accordance with the invention is delivered directly into the tendon/ligament tissue (e.g. by injection).

**[0013]** In yet another embodiment the present invention provides for prophylaxis and prevention, respectively, of the progression of a ligament or tendon lesion, a ligament or tendon injury or damage, a (degenerative) ligament or tendon disease or disorder or (degenerative) ligamentopathy and (degenerative) tendinopathy, respectively, like, for example, prophylaxis/prevention of the progression of lateral epicondylitis. In particular, the present invention provides for the liquid composition containing naked RNA of the invention for use in prophylaxis and prevention, respectively, of the progression of a ligament or tendon lesion, a ligament or tendon injury or damage, a (degenerative) ligament or tendon disease or disorder or (degenerative) ligamentopathy and (degenerative) tendinopathy. Again, what has been said herein elsewhere with respect to the mode of administration applies here, *mutatis mutandis*. In particular, it is envisaged that the liquid composition containing naked RNA to be used in accordance with the invention is delivered directly into the tendon/ligament tissue (e.g. by injection).

**[0014]** In a specific aspect, the prophylaxis and prevention, respectively, in accordance with the invention may start once (a) first symptom(s) have/has been observed. For example, such a symptom is pain and/or tenderness (for example pain and/or tenderness in the bony knob on the outside of the elbow in the case of lateral epicondylitis).

**[0015]** In any case, Lateral epicondylitis is a prominent, however non-limiting, example of a ligament/tendon lesion and (degenerative) ligamentopathy/tendinopathy, respectively, to be treated in accordance with the invention.

**[0016]** The term "naked RNA" means that the RNA is not complexed to any kind of other compound, in particular proteins, peptides, polymers, like cationic polymers, lipids, liposomes, viral vectors or the like. Thus, "naked RNA" means that the RNA is present in the liquid composition in a free and uncomplexed form being molecularly dispersed in solution. For example, it is not envisaged that the "naked RNA" is complexed with a lipid and/or polymer carrier system/transfection reagent like, for example, DreamFect™ Gold or (branched) PEI. Hence, the liquid composition of the invention does, for example, not contain a lipid and/or polymer carrier system/transfection reagent like, for example, DreamFect™ Gold or (branched) PEI.

**[0017]** According to the present invention the naked RNA is present in a liquid composition which is used for application to the ligament or tendon tissue, wherein the RNA is solved in a glucose solution. A liquid composition is any composition in which the RNA is present in solution in a liquid. The solution is preferably an aqueous solution. Thus, the liquid may be water, preferably sterile water, more preferably "water for injection" (WFI) or any other buffered or unbuffered aqueous solution. In one aspect of the present disclosure, the liquid composition is an unbuffered solution, preferably a salt solution, more preferably a salt solution of a

pharmaceutically acceptable salt, even more preferably an NaCl solution, i.e. saline. Preferably, the salt solution is isotonic and even more preferably it shows a physiological pH value (see below).

In another embodiment the solution in which the RNA is contained is a buffered solution. Preferably, such a solution is isotonic to blood and contains a buffer. In principle any buffer which effectively buffers in the physiological range, in particular in the range of pH 3.0 to 10.5 and more preferably pH 4.0 to 9.0, can be used. Preferable buffers are acetate, phosphate, carbonate, lactate and citrate buffers.

An example for an aqueous buffered solution is Ringer's solution. Ringer's solution is a solution of several salts dissolved in water for the purpose of creating an isotonic solution relative to the bodily fluids of a subject. It typically contains sodium chloride, potassium chloride, calcium chloride and sodium bicarbonate, wherein the latter one is included in order to balance the pH value. A standard Ringer's solution is prepared by dissolving 6.5 g NaCl, 0.42 g KCl, 0.25 g CaCl<sub>2</sub> and 1 mole of sodium bicarbonate in one liter of distilled water. Ringer's solution may optionally also contain ATP or dextrose as well as antibiotics or antifungals. In a preferred embodiment, the Ringer's solution is a lactated or acetated Ringer's solution. Lactated Ringer's solution is a solution that is isotonic with blood and normally intended for intravenous administration. One liter of lactated Ringer's solution contains 130 mEq of sodium ion (=130 mmol/L), 109 mEq of chloride ion (= 109 mmol/L), 28 mEq of lactate (= 28 mmol/L), 4 mEq of potassium ion (= 4 mmol/L), 3 mEq of calcium ion (= 1.5 mmol/L) and has an osmolarity of 273 mOsm/L. Acetated Ringer's solution generally contains calcium ions (c=0.9 mmol/l), potassium ions (c=5.4 mmol/l), magnesium ions (c=1.0 mmol/l), sodium ions (c=130 mmol/l), acetate ions (c=27 mmol/l) and chloride ions (c=112 mmol/l).

**[0018]** The liquid composition to be used in accordance with the invention is a glucose solution containing the RNA. The concentration of the glucose is preferably in the range of 0.1-15% (m/v), more preferably in the range of 1-10% (m/v), even more preferably in the range of 2-8% (m/v) and particularly preferred in the range of 3.75-6.25% (m/v). It is especially preferred that the glucose concentration is in the range of 5% (m/v) ± 0.2% even more preferably in the range of 5% (m/v) ± 0.1 %.

It is preferred that the glucose solution is a buffered solution. In principle any buffer can be used for buffering the glucose solution. The buffer is preferably a buffer which is able to maintain a pH value in the physiological range, i.e., in the range of pH 3.0 to 10.5, more preferably in the range of pH 4.0 to 9.0, even more preferably in the range of pH 5.0 to 8.0 and particularly preferred in the range of pH 7.3 to 7.5.

In a preferred embodiment the buffer classifies as a "Good's buffer". "Good's buffers" are buffers which have been described by Norman Good and colleagues during the period of 1966 to 1980 (Good et al., *Biochemistry* 5 (1966), 467-477; Good et al., *Methods Enzymol.* 24 (1972), 53-6; Ferguson et al., (*Anal. Biochem.* 104 (1980), 300-310)). Good's buffers are selected so as to fulfill the following criteria as far as this is possible:

pK<sub>a</sub>: Because most biological reactions take place at near-neutral pH between 6 and 8, ideal buffers would have pK<sub>a</sub> values in this region to provide maximum buffering capacity there.

Solubility: For ease in handling and because biological systems are in aqueous systems, good solubility in water was required. Low solubility in nonpolar solvents (fats, oils, and organic solvents) is also considered beneficial, as this would tend to prevent the buffer compound from accumulating in nonpolar compartments in biological systems: cell membranes and other cell compartments.

Membrane impermeability: Ideally, a buffer will not readily pass through cell membranes, this will also reduce the accumulation of buffer compound within cells.

Minimal salt effects: Highly ionic buffers may cause problems or complications in some biological systems.

Influences on dissociation: There should be a minimum influence of buffer concentration, temperature, and ionic composition of the medium on the dissociation of the buffer.

Well-behaved cation interactions: If the buffers form complexes with cationic ligands, the complexes formed should remain soluble. Ideally, at least some of the buffering compounds will not form complexes.

Stability: The buffers should be chemically stable, resisting enzymatic and non-enzymatic degradation.

Biochemical inertness: The buffers should not influence or participate in any biochemical reactions.

Optical absorbance: Buffers should not absorb visible or ultraviolet light at wavelengths longer than 230 nm so as not to interfere with commonly used spectrophotometric assays.

Ease of preparation: Buffers should be easily prepared and purified from inexpensive materials.

Examples of Good's buffers, which are also preferably employed in the present invention are set forth in the following Table.

Table 1

Buffer	pK <sub>a</sub> 20°C	at $\Delta$ pK <sub>a</sub> /°C	Solubility in water at 0°C
MES	6.15	-0.011	0.65M
ADA	6.62	-0.011	-
PIPES	6.82	-0.0085	-
ACES	6.88	-0.020	0.22M
MOPSO	6.95	-0.015	0.75M

Cholamine Chloride	7.10	-0.027	4.2M (As HCl)
MOPS	7.15	-0.013	Large
Buffer	pK <sub>a</sub> 20°C	at $\Delta$ pK <sub>a</sub> /°C	Solubility in water at 0°C
BES	7.17	-0.016	3.2M
TES	7.5	-0.020	2.6M
HEPES	7.55	-0.014	2.25M
DIPSO	7.6	-0.015	0.24M
Acetaminoglycine	7.7	-	Very large
TAPSO	7.7	-0.018	1.0M
POPSO	7.85	-0.013	-
HEPPSO	7.9	-0.01	2.2M
HEPPS	8.1	-0.015	Large
Tricine	8.15	-0.021	0.8M
Glycinamide	8.2	-0.029	6.4M (As HCl)
Bicine	8.35	-0.018	1.1M
TAPS	8.55	-0.027	Large

MES: 2-(*N*-morpholino)ethanesulfonic acid  
 ADA: *N*-(2-Acetamido)iminodiacetic acid  
 PIPES: piperazine-*N,N'*-bis(2-ethanesulfonic acid  
 ACES: *N*-(2-Acetamido)-2-aminoethanesulfonic acid  
 MOPSO: 3-Morpholino-2-hydroxy-propanesulfonic acid  
 MOPS: 3-(*N*-morpholino)propanesulfonic acid  
 BES: *N,N*-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid  
 TES: 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid  
  
 HEPES: 2-(4-(2-Hydroxyethyl)- 1-piperazinyloxy)-ethansulfonsäure

DIPSO:	3-(N,N-Bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid
TAPSO:	3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]-2-hydroxypropane-1-sulfonic acid
POPSO:	2-hydroxy-3-[4-(2-hydroxy-3-sulfopropyl)piperazin-1-yl]propane-1-sulfonic acid
HEPPSO:	N-(2-Hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)
HEPPS:	3-[4-(2-hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid
Tricine:	N-(2-Hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine
Bicine:	2-(Bis(2-hydroxyethyl)amino)acetic acid
TAPS:	3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propane-1-sulfonic acid

**[0019]** The different above mentioned Good's buffers fulfill the selection criteria to various degrees and no buffer is completely inert in biological systems. Further examples for Good's buffers which have been identified in the meantime are AMPSO (N-(1,1-Dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid), CABS (4-(Cyclohexylamino)-1-butanesulfonic acid), CHES (N-Cyclohexyl-2-aminoethanesulfonic acid), CAPS (N-cyclohexyl-3-aminopropanesulfonic acid) and CAPSO (N-cyclohexyl-2-hydroxyl-3-aminopropanesulfonic acid).

**[0020]** In a particularly preferred embodiment the buffer is 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfonsaure (HEPES), i.e. the glucose solution is a HEPES buffered glucose solution (also referred to herein as HBG). As shown in the appended Examples, an efficient expression of mRNA in tendon tissue can be achieved if mRNA, for example encoding (human) BMP-7 or a reporter protein (luciferase), is injected into ligament or tendon tissue in the form of an aqueous solution, e.g. in saline solution or in different buffered solutions such as acetated or lactated Ringer's solution. A particularly high expression can be achieved if the mRNA is administered in HEPES buffered glucose (HBG), pH 7.4.

More preferably the HBG is a HBG with a concentration in the range of 0.75 x HBG to 1.25 x HBG, more preferably, 0.8 x HBG to 1.2 x HBG, even more preferably, 0.9 x HBG to 1.1 x HBG, and particularly preferred 1 x HBG with 1 x HBG being. The term "1 x HBG" refers to a solution with the following composition: 25 mM HEPES; 5% glucose m/v.

**[0021]** In one embodiment, the liquid composition of the invention does not contain (an) amino acid(s) and/or ammonium,

**[0022]** The concentration of the RNA in the liquid composition is not particularly crucial and can be adjusted as required. Preferably, the concentration lies in the range of 0.1 to 5,0 µg/µl, or in the range of 0.25 to 2.5 µg/µl, more preferably in the range of 0.5 to 2.0 µg/µl, more preferably in the range of 0.75 to 1.5 µg/µl, even more preferably in the range of 0.80 to 1.20 µg/µl, particularly preferred in the range of 0.90 to 1.10 µg/µl.

**[0023]** The liquid composition containing the RNA can be applied to the ligament or tendon tissue by means known to the person skilled in the art, preferably by injection (direct/local injection), typically by using a syringe with a needle. In principle any commercially available syringe in combination with a needle can be used for this purpose. Preferred are hypodermic needles. As is evident from the appended Examples, the size of the needle, in particular the diameter of the needle, used for injecting the liquid composition containing the RNA may have an influence on the effectiveness of the expression/activity of the RNA in the ligament or tendon tissue. The diameter of a needle is indicated by the needle gauge (G; according to the Stub's Needle Gauge). Typically needles in medical use range from 7G (the largest) to 33G (the smallest). In a preferred embodiment, the needle used for injecting the liquid composition containing the RNA has a diameter in the range of 20G to 27G, preferably in the range of 21G to 26G, more preferably in the range of 22G to 25G, even more preferably 23G or 24G. Particularly preferred are needles with a diameter of 23G.

**[0024]** The RNA contained in the liquid composition can be any RNA as defined in the claims. Thus, in principle any type of RNA as defined in the claims can be employed in the context of the present invention. In one preferred embodiment the RNA is a single-stranded RNA. The term "single-stranded RNA" means a single consecutive chain of ribonucleotides in contrast to RNA molecules in which two or more separate chains form a double-stranded molecule due to hybridization of the separate chains. The term "single-stranded RNA" does not exclude that the single-stranded molecule forms in itself double-stranded structures such as loops, secondary or tertiary structures.

The term "RNA" covers RNA which codes for an amino acid sequence as well as RNA which does not code for an amino acid sequence. It has been suggested that more than 80 % of the genome contains functional DNA elements that do not code for proteins. These noncoding sequences include regulatory DNA elements (binding sites for transcription factors, regulators and coregulators etc.) and sequences that code for transcripts that are never translated into proteins. These transcripts, which are encoded by the genome and transcribed into RNA but do not get translated into proteins, are called noncoding (ncRNAs). Thus, it is also disclosed herein that the RNA is a noncoding RNA. Preferably, the noncoding RNA is a single-stranded molecule. Studies demonstrate that ncRNAs are critical players in gene regulation, maintenance of genomic integrity, cell differentiation, and development, and they are misregulated in various human diseases. There are different types of ncRNAs: short (20-50 nt), medium (50-200 nt), and long (>200 nt) ncRNAs. Short ncRNA includes microRNA (miRNA), small interfering RNA (siRNA), piwi-interacting RNA (piRNA), and transcription initiating RNA (tiRNA). Examples of medium ncRNAs are small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), transfer RNAs (tRNAs), transcription start-site-associated RNAs (TSSaRNAs), promoter-associated small RNAs (PASRs), and promoter upstream transcripts (PROMPTS). Long noncoding RNAs (lncRNA) include long-intergenic noncoding RNA (lincRNA), antisense-lncRNA, intronic lncRNA, transcribed ultra-conserved RNAs (T-UCRs), and others (Bhan A, Mandal SS, Chem Med Chem. 2014 Mar 26. doi: 10.1002/cmdc.201300534). Of the above-mentioned non-coding RNAs only siRNA is double-stranded. Thus, if the noncoding RNA is single-stranded, it is not siRNA. In a particularly preferred embodiment the RNA is a coding RNA, i.e. an RNA which codes for an amino acid

sequence. Such RNA molecules are also referred to as mRNA (messenger RNA) and are single-stranded RNA molecules, The RNA may be made by synthetic chemical and enzymatic methodology known to one of ordinary skill in the art, or by the use of recombinant technology, or may be isolated from natural sources, or by a combination thereof. The RNA may optionally comprise unnatural nucleotides.

**[0025]** The RNA in accordance with the invention refers to mRNA and most preferably to modified mRNA, in particular to modified mRNA as described herein below and, for example, in WO 2011/012316. The mRNA encodes a polypeptide as defined in the claims which can have a positive effect on the healing process of ligament or tendon lesions. Thus, the polypeptide is a polypeptide which has a beneficial effect on the healing process of ligament or tendon lesions, in particular a polypeptide which is therapeutically active in the healing process of ligament or tendon. Examples for such polypeptides are growth factors and cytokines. Examples for growth factors are platelet-derived growth factor (PDGF), FGF (fibroblast growth factor) such as basic fibroblast growth factor (bFGF), insulin-like growth factor 1(IGF-1), transforming growth factor  $\beta$ 1 (TGF- $\beta$ 1). epidermal growth factor (EGF). Without being bound by theory, both, FGF and TGF- $\beta$  (TGF- $\beta$ 1) are important/involved in the parallel organization of collagen fibrils. Other Examples are growth and differentiation factors (GDFs) which are a subfamily of the bone morphogenic proteins (BMPs) and are involved in the embryonic development of different organs. GDF 5, 6 (BMP-13) and 7 (BMP-12) are particularly preferred since they have been shown to lead to the ectopic formation of ligaments and tendons when injected into rats (Evans, CH, Sports Med. 28 (1999), 71-76). A further and preferred example for a growth factor is BMP-7, for example as encoded by a nucleotide sequence as depicted in SEQ ID NO. 1, 2 or 3 (see also, for example, Pubmed accession number: NM\_001719: Version: NM\_001719.2, GI:187608319; [http://www.ncbi.nlm.nih.gov/nucore/NM\\_001719.2](http://www.ncbi.nlm.nih.gov/nucore/NM_001719.2) (non-codon-optimized sequence including exons; the coding sequence starts at nt948 and ends, without interruptions, at nt4031)).

Other herein disclosed examples for proteins which can be encoded by the mRNA are transcription factors to activate the regeneration program in tendons/ligaments or inhibit anti-regenerative cellular programs in tendons/ligaments, e.g. EGR1/2, Scleraxis, Mohawk and Sox9 (Guerquin et al., J. Clin. Invest. 123 (2013), 3564-3576; Huanhuan Liu et al., Cell and Tissue Research 356(2014), 287-298). Further examples for proteins to be encoded by the herein disclosed mRNA are structural proteins such as collagens or proteoglycans.

**[0026]** Further examples for proteins which can be encoded by the herein disclosed mRNA are the following: FBJ osteosarcoma oncogene B (Fosb), FBJ osteosarcoma oncogene (c-Fos), Regulator of G protein signaling-1 (Rgs1), Galanin-like peptide (Galp), Early growth response protein-1 (Egr1). Early growth response protein-2 (Egr2), NK6 homeobox 1 (Nkx), Similar to ribosomal protein s10 (LOC688706), Similar to testis-specific farnesyl pyrophosphate synthetase (RGD1565157), Frizzled homolog 9 (Fzd9), Aldehyde oxidase-1 (Aox-1), Selenium binding protein 1 (Selenbp1), Mitogen-activated protein kinase kinase kinase 13 (Map3k13), Aggrecan, Adamts-4, Alox-5, Ptges, iNOS, IL-1, IL-1 receptor antagonist, Angpoietin 1, Angpoietin like 1, Vegf, Pappa, Fmo2, C1qTNF3, Fabp4, Scleraxis, Tendomodulin, F2r12, F3, and F5, tgf- 3, mdk, and bmp-6, keratocan, and fibromodulin, coll VIII, coll XI, coll I, Amot,

Epha3, Epha4, Fgf-2, Calp6, Enpp2, Fmo1-4, MaoB, Nox4, Xdh, Hmox1, S100a9, Pappa, Arklc14, Arklc19, Gstt2, Gstm5, Gstm7, Hasph1, Hsph8, Hspa1b, Six1, Six2, growth and differentiation factors (GDFs, GDF1-11, GDF15), Smad8, Homer-1b, Metabotropic glutamate receptor type 1, Histamine H2-receptor, Vegetal related, Secreted NK cell receptor 2B4, 5-lipoxygenase, Preproepidermal growth factor, Immunoglobulin lambda-5 chain, Lumican, Betacellulin, rSec8, Sonic hedgehog, LIM homeobox protein 7, Frizzled, ZOG, Notch 3 protein. Tissue inhibitor of metalloproteinase type 2, N-methyl-D-aspartate receptor subunit 2C, T-cell marker CD2 antigen, Glutamate receptor interacting protein 2, Synapsin 2b, Hepatocyte growth factor, T-cell receptor active beta-chain V-region, Growth factor receptor-bound protein 14, Fibroblast growth factor receptor-3, Vegetal related, High-affinity glutamate transporter and Homeobox protein rPtx2. The genes encoding these proteins have been reported to be dysregulated during regeneration of tendon tissue.

**[0027]** In one embodiment, the administration of two or more (e.g. 3, 4 or 5) mRNAs each encoding a different polypeptide as described herein and, in particular, as described above is envisaged. In this context, administration may be simultaneously (preferred) or sequentially. Likewise, the administration of an mRNA which encodes two or more (e.g. 3, 4 or 5) of the polypeptides as described herein and, in particular, as described above may be applied.

**[0028]** In the context of this embodiment, it is preferred that the two or more (e.g. 3, 4 or 5) polypeptides are selected from the group consisting of PDGF, FGF such as bFGF, IGF-1, TGF-1, EGF, a GDF and BMP. In this context, the GDF may be GDF 5, 6 (BMP-13), 7 (BMP-12) and/or myostatin (GDF-8) and/or the BMP may be BMP-7.

**[0029]** The term "mRNA" (i.e. messenger RNA) refers to polymers which are built up of nucleoside phosphate building blocks mainly with adenosine, cytidine, uridine and guanosine as nucleosides, and which contain a coding region encoding a polypeptide. In the context of the present invention, mRNA should be understood to mean any polyribonucleotide molecule which, if it comes into the cell, is suitable for the expression of a polypeptide or fragment thereof or is translatable to a polypeptide or fragment thereof. The term "polypeptide" here encompasses any kind of amino acid sequence, i.e. chains of two or more amino acids which are each linked via peptide bonds and also includes peptides and fusion proteins.

The mRNA contains a ribonucleotide sequence which encodes a polypeptide or fragment thereof whose function in the cell or in the vicinity of the cell is needed or beneficial, in particular in the context of the healing of ligament or tendon lesions. The mRNA may contain the sequence for the complete polypeptide or a functional variant thereof. Further, the ribonucleotide sequence can encode a polypeptide which acts as a factor, inducer, regulator, stimulator or enzyme, or a functional fragment thereof, where this polypeptide is one whose function is necessary in order to remedy a disorder, in particular a ligament or tendon lesion.

Here, functional variant is understood to mean a fragment which in the cell can undertake the function of the polypeptide whose function in the cell is needed. In addition, the mRNA may also have further functional regions and/or 3' or 5' noncoding regions. The 3' and/or 5' noncoding regions can be the regions naturally flanking the polypeptide-encoding sequence or artificial sequences which contribute to the stabilization of the RNA. Those skilled in the art can

determine the sequences suitable for this in each case by routine experiments.

In a preferred embodiment, the mRNA contains an m7GpppG cap, an internal ribosome entry site (IRES) and/or a polyA tail at the 3' end in particular in order to improve translation. The mRNA can have further regions promoting translation.

**[0030]** In a preferred embodiment the RNA, preferably the mRNA, is an RNA which contains a combination of modified and unmodified nucleotides. Preferably, it is an (m)RNA containing a combination of modified and unmodified nucleotides as described in WO2011/012316. The mRNA described therein is reported to show an increased stability and diminished immunogenicity. In a preferred embodiment, in such a modified mRNA 5 to 50% of the cytidine nucleotides and 5 to 50% of the uridine nucleotides are modified. The adenosine- and guanosine-containing nucleotides can be unmodified. The adenosine and guanosine nucleotides can be unmodified or partially modified, and they are preferably present in unmodified form. Preferably 10 to 35% of the cytidine and uridine nucleotides are modified and particularly preferably the content of the modified cytidine nucleotides lies in a range from 7.5 to 25% and the content of the modified uridine nucleotides in a range from 7.5 to 25%. It has been found that in fact a relatively low content, e.g. only 10% each, of modified cytidine and uridine nucleotides can achieve the desired properties. It is particularly preferred that the modified cytidine nucleotides are 5-methylcytidin residues and the modified uridine nucleotides are 2-thiouridin residues. Most preferably, the content of modified cytidine nucleotides and the content of the modified uridine nucleotides is 25%, respectively.

**[0031]** In another preferred embodiment, the RNA, preferably the mRNA, may be combined with target binding sites, targeting sequences and/or with micro-RNA binding sites, in order to allow activity of the desired RNA only in the relevant cells. In a further preferred embodiment, the RNA can be combined with micro-RNAs or shRNAs downstream of the 3' polyA tail.

**[0032]** Preferably, the naked RNA to be employed in the context of the present invention, in particular the naked mRNA, is codon-optimized. A non-limiting example of a codon-optimized and chemically modified (m)RNA to be employed in the context of the invention is the codon-optimized BMP-7-encoding mRNA as depicted in SEQ ID NO. 2 or 3. The skilled person is readily in the position to codon-optimize a given (m)RNA by relying on respective means and methods known in the art. For example, codon optimization may be performed by using Eurofins "GENEius" software (see, for example, [https://www.eurofinsgenomics.eu/media/892634/an\\_geneius\\_compared-to-competitors.pdf](https://www.eurofinsgenomics.eu/media/892634/an_geneius_compared-to-competitors.pdf)). Moreover, the skilled person is readily in the position to chemically modify a given (m)RNA by relying on respective means and methods known in the art (see, for example, WO 2011/012316).

**[0033]** The present invention also relates to mRNA encoding a polypeptide as defined in the claims, for use in the treatment of ligament or tendon lesions wherein the RNA is administered to, in particular directly into, the ligament or tendon (preferably by injection) in the form of a liquid composition wherein the RNA is contained as naked RNA. As regards the way of administration and the characteristics of the composition and the RNA contained therein, the

same applies as has been set forth herein elsewhere.

**[0034]** Also disclosed herein is a method for treating (or preventing) ligament or tendon lesions comprising the administration (of a pharmaceutically effective amount) of a liquid composition containing naked RNA, preferably mRNA encoding a polypeptide (e.g. BMP-7), which is beneficial in the process of healing the ligament or tendon lesion to the ligament or tendon (to a patient in need thereof). As regards the way of administration and the characteristics of the composition and the RNA contained therein, the same applies as has been set forth herein elsewhere.

**[0035]** In a preferred embodiment, the liquid composition and naked RNA, respectively, of the present invention is to be administered to, in particular directly into, the ligament or tendon. In this context, the most preferred way of administration is injection, i.e. intra-ligament or intra-tendon injection.

**[0036]** It is, in principle, envisaged in the context of the invention to administer the liquid composition and naked RNA, respectively, as early as possible, i.e. at the earliest possible stage of the ligament/tendon lesion and (degenerative) ligamentopathy/tendinopathy, respectively. For example, this stage is once (a) first symptom(s) have/has been observed (e.g. pain or tenderness) or once a surgical intervention starts or during a surgical intervention. This applies to both, the acute and chronic forms of the lesions/diseases/disorders to be treated or prevented in accordance with the invention. However, any possible point of time after the diagnosis is possible and worthwhile and, hence, envisaged in accordance with the invention. For example, in case there is a surgical intervention (for example following a ligament/tendon rupture) the liquid composition and naked RNA, respectively, may be administered already during, but at least shortly after, the surgical intervention. When administered during surgical intervention, the liquid composition and naked RNA, respectively, may be administered to (for example by injection into) one of or both tails of the rupture.

**[0037]** In a specific embodiment, the liquid composition and naked RNA, respectively, is to be administered during or even before the inflammatory and early proliferative phase, respectively, of ligament/tendon regeneration. For example, administration may be during day 0 to day 10, preferably during day 0 to day 7, post injury/post lesion. More specifically, administration may be at day 0, 1, 2, 3, 4, 5, 6 or 7 post injury/post lesion. Preferably, administration is at day 1 and even more preferably at day 0 post injury/post lesion.

**[0038]** The administration of the liquid composition and naked RNA, respectively, in accordance with the invention may, for example depending on the course of the lesion/disease/disorder to be treated/prevented, be repeated at least once but preferably several times (for example 3 to 5 times). The repeated administration may be every few weeks (for example every 1, 2, 3, or 4 weeks) up to every few days (for example every 1, 2, 3, 4, 5 or 6 days).

**[0039]** The liquid composition and naked RNA, respectively, of the invention can be

administered to a patient at a suitable dose. The dosage regimen can be determined by the attending physician, for example based on clinical factors. As is well known in the medical arts, dosages for any one patient depend upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. However, the skilled person/the attending physician is readily in a position to (a) deduce (therapeutically) effective concentration(s) and/or dosages of the active substance(s) to be administered, e. g. *in vivo* or *ex vivo*. Corresponding samples may be taken from, for example, the ligament or tendon (e.g. by a suitable probe) and the active compounds (naked RNA) may be detected and their corresponding concentrations may be determined in said samples, for example by HPLC.

The determination of the active compound concentrations may be obtained in human patients, healthy (human) individuals as well as in animals (e.g. mice, rats, pigs, horses and the like), like laboratory animals, non-human transgenic animals (e.g. transgenic mice, rats, pigs, and the like). It is envisaged that the determination of active compound concentrations in, e. g. the ligament or tendon, may, for example, be deduced in (healthy) volunteers and corresponding administration schemes for (human) patients may be established. For example, the dosage dependencies (e.g. dosage administered versus concentration-/dosage detected (in various regions of) the ligament or tendon may be determined by standard methods known in the art. Further methods comprise, but are not limited to, the detection of labelled peptides *in vivo* (e.g. by corresponding labelling techniques, like radioactive labelling, fluorescent labelling, etc.) or physiological/biochemical assays. Accordingly, the dosage of active compounds to be administered in order to obtain a desired concentration of the active compounds (in a certain part of the ligament/tendon) may be deduced. These and other methods to deduce such concentrations are known in the art.

**[0040]** A typical dose of active substances (e.g. naked RNA) can be, for example, in the range of 1 ng to several grams, preferably in the range of 0.1 µg to 1 g, preferably in the range of 1 µg to 0.1 g, preferably in the range of 10 µg to 10 mg, and most preferably in the range of 100 µg to 1 mg. This particularly applies to a human patient. Applied to (m)RNA therapy, the dosage of an (m)RNA for expression (or for inhibition of expression) should correspond to this range; however, doses below or above this exemplary range are, in principle, also envisioned, especially considering the aforementioned factors. Generally, the regimen as a regular administration of the liquid composition should be in the range of 0.1 µg to 10 mg units, preferably in the range of 1 µg to 1 mg units, more preferably in the range of 10 µg to 0.1 mg units per kilogram of body weight per day. Again, this is particularly applies to a human patient. Progress can be monitored by periodic assessment. Dosages may vary but a preferred dosage for administration by injection of (m)RNAs as constituents of the liquid composition of the present invention is from approximately  $10^5$  to  $10^{15}$  copies of the (m)RNA molecule per injection. Again, this particularly applies to a human patient.

**[0041]** In particular, the liquid composition of the invention is envisaged to be administered to a patient, preferably to a human patient/a human. However, the herein described ligament or tendon lesions (and related conditions) may also be treated (or prevented) in a non-human

animal subject/patient like, for example, a pet (e.g. dog, cat, rabbit, rat and mouse), a cattle (e.g. cow, pig, sheep), a horse (e.g. a race horse) or pony or a bird (e.g. chicken, turkey, parrot).

**[0042]** Any of the liquid compositions of the invention may be provided together with an instruction manual or instruction leaflet. The instruction manual/leaflet may comprise guidance for the skilled person/attending physician how to treat (or prevent) a disease or disorder as described herein (ligament or tendon lesion) in accordance with the invention. In particular, the instruction manual/leaflet may comprise guidance as to the herein described mode of delivery/administration and delivery/administration regimen, respectively (for example route of delivery/administration, dosage regimen, time of delivery/administration, frequency of delivery/administration). In particular, the instruction manual/leaflet may comprise the instruction that the liquid composition and naked RNA, respectively, is to be injected and/or is prepared for injection into the ligament or tendon. The instruction manual/leaflet may further comprise the instruction that the liquid composition and naked RNA, respectively, is prepared for administration during the inflammatory phase which follows the ligament or tendon lesion. In principle, what has been said herein elsewhere with respect to the mode of delivery/administration and delivery/administration regimen, respectively, may be comprised as respective instructions in the instruction manual/leaflet .

**[0043]** Also disclosed herein is a HEPES-buffered glucose solution comprising naked RNA, preferably an mRNA encoding a polypeptide (e.g. BMP-7). As regards the preferred embodiments of the solution and the RNA, the same applies as has been set forth herein elsewhere.

**[0044]** Furthermore, the present invention also relates to a therapeutic composition containing mRNA encoding a polypeptide as defined in the claims (e.g. BMP-7), which is therapeutically active in the healing process of ligament or tendon. The therapeutic composition is a liquid formulation in which the RNA is present in the form of naked RNA, and wherein the composition is a glucose solution containing the naked RNA. As regards the way of administration and the characteristics of the composition and the RNA contained therein, the same applies as has been set forth herein elsewhere.

**[0045]** The liquid composition for use according to the invention may be provided in (or in form of) a kit/a kit of contents. The kit may comprise one or more of the components of the liquid composition of the invention, for example in one or more separate containers. For example, the kit may comprise the naked RNA (e.g. in dried form), a solubilizer and (buffered or unbuffered) aqueous solution, for example in one, two or three (or more) separate containers, respectively. The kit may also comprise the instruction manual or instruction leaflet.

### **Figure legends**

**[0046]**

**Figure 1**

shows the expression of naked mRNA coding for firefly luciferase (FFL) in HBG pH 7.4 (1x) versus mRNA coding for firefly luciferase (FFL) in different carrier systems in bovine and ovine tendon (see Example 1).

**Figure 2**

shows the expression of firefly luciferase (FFL) encoding mRNA in tendons of different species (see Example 2). The data represent the expression level 24h after injection.

**Figure 3**

shows the kinetics of the expression of firefly luciferase (FFL) encoding mRNA of different mRNA concentrations in ovine tendon explants (see Example 3).

**Figure 4**

shows the comparison of different solvents used for naked mRNA injection into bovine tendon explants (see Example 4).

**Figure 5**

shows a comparison of expression of firefly luciferase (FFL) encoding mRNA in bovine tendon explants when injected in water-for-injection (WFI), NaCl (isotonic saline) and HBG (1x) pH 7.4 (see Example 5).

**Figure 6**

shows the influence of the HBG concentration on the expression level of firefly luciferase (FFL) encoding mRNA in bovine tendon explants (see Example 6).

**Figure 7**

shows the influence of the amount of mRNA on the expression level of firefly luciferase (FFL) encoding mRNA in ovine tendon explants (see Example 7).

**Figure 8**

shows the influence of the mRNA concentration on the expression level of firefly luciferase (FFL) encoding mRNA in bovine tendon explants (see Example 8).

**Figure 9**

shows the influence of the needle size on the expression level of firefly luciferase (FFL) encoding mRNA in ovine tendon explants (see Example 9).

**Figure 10a**

shows intact ovine deep digital flexor tendon. High expression in the injected area of the tendon 24 hours after SNIM®-FFL-RNA (WO 2011/012316) injection (see Example 10).

**Figure 10b**

shows mild damaged tendon by injection of 100 CDU. High expression in the injected peripheral area of the defect (see Example 10).

**Figure 10c**

shows moderate damaged tendon by injection of 200 CDU. Punctual expression in the peripheral area of the defect. Tendon was opened longitudinally prior to the incubation in luciferin (see Example 10).

**Figure 10d**

shows severe damaged tendon by injection of 500 CDU. Punctual expression in the peripheral area of the defect. Tendon was cut before incubation in luciferin solution (see Example 10).

**Figure**

**11A** Longitudinal section of ovine tendons 24 hours post modified LacZ mRNA injection and LacZ staining. Blue precipitate is detectable in the central area of the tendon (see Example 11).

**Figure 11B**

Longitudinal section of untreated control ovine tendons and LacZ staining. Blue precipitate is not detectable in the central area of the tendon (see Example 11).

**Figure 11C**

Microscopic images of a longitudinal section of ovine tendons 24 hours post modified LacZ mRNA injection and LacZ staining. Blue precipitate is detectable in cells between tendon fibers (see Example 11).

**Figure 11D**

Microscopic images of a longitudinal section of untreated control ovine tendons and LacZ staining. Blue precipitate is not detectable in cells between tendon fibers (see Example 11).

**Figure 12A**

Microscopic images of a longitudinal section of BMP7-immunohistochemistry of modified BMP7 mRNA treated rat Achilles tendon 24 hrs after injection. Red/purple staining is detectable in cells between tendon fibers (see Example 12).

**Figure 12B**

Microscopic images of a longitudinal section of a control untreated rat Achilles tendon. Red/purple staining is not detectable in cells between tendon fibers (see Example 12).

**Figure 13**

$^{125}$ I marked mRNA was injected into porcine tendon and radioisotopically imaged 30 min later (upper tendon). Lower tendon act as negative control. (see Example 13). mRNA slowly diffuses away from the site of injection.

**Figure 14**

Protein expression in intact tendon explants after naked mRNA injection. (A) Bioluminescence imaging (BLI) 24 hours after cmRNA<sup>LUC</sup> injection in tendon explants of different species. Either 26.6  $\mu$ g [0.65 mg/ml] (rat), 50  $\mu$ g [0.5 mg/ml] (bovine, equine) or 100  $\mu$ g [1 mg/ml] (porcine, ovine) of naked cmRNA<sup>LUC</sup> was injected. Expression was detected in all species tested. (B) Luciferase expression is dose-dependent. Porcine tendon explants were injected with either 25  $\mu$ g, 50  $\mu$ g, 100  $\mu$ g or 200  $\mu$ g of cmRNA<sup>LUC</sup> in 250  $\mu$ l of isotonic saline solution (NaCl). Mean expression  $\pm$  SEM of 24 hour point of time is shown (n=4). (C) Porcine tendon explants showing macroscopically blue precipitate spread in a tube-like manner 24 hours after cmRNA<sup>LacZ</sup> injection and X-Gal staining. (D) Control explants 24 hours after cmRNA<sup>LUC</sup> injection and X-Gal staining. (E, F, G, H) Sections of LacZ stained cmRNA<sup>LacZ</sup> injected (E, G) and cmRNA<sup>LUC</sup> injected porcine tendons (F, H) counterstained with hematoxylin.  $\beta$ -galactosidase was locally expressed near the injection site (E) and could be detected in tenocytes (G) and connective tissue, while cmRNA<sup>LUC</sup> treated controls were negative for  $\beta$ -gal activity (F, H). E, F Original magnification x20. G, H Original magnification x40. (I, J, K, L)

Immunostaining of BMP-7 in sections of cmRNA<sup>BMP-7</sup> treated rat Achilles tendons (I, K) and untreated controls (J, L) counterstained with hematoxylin. Positive signals were stained red. BMP-7 is increasingly detectable in vascular walls, connective tissue (I) as well as in tenocytes (K) in cmRNA<sup>BMP-7</sup> treated tendons. I, J Original magnification x10. K, L Original magnification x40.

### Figure 15

Expression kinetics and comparison of different solvents used for naked mRNA injection. (A) Kinetics of luciferase expression in bovine tendon explants. 50 µg cmRNA<sup>LUC</sup> [0.5 mg/ml] in isotonic saline solution was injected. Data represents mean expression levels ± SEM after 24h, 48h and 72h post injection (n ≥ 10). Highest luciferase expression was measured after 24 hours post injection. Within 72 hours luciferase activity decreased to background levels. (B) 50 µg cmRNA<sup>LUC</sup> [0.25 mg/ml] in different solvents were injected in bovine tendon explants (n ≥ 5). Vertical axis shows FFL expression values, while horizontal axis shows different solvents that were used for dilution. Data represents average expression levels ± SEM 24 hours post injection. Significantly enhanced expression was observed with HBG 5% (15-fold) compared to cmRNA<sup>LUC</sup> dissolved in saline solution (\*, p < 0.05) and (57-fold) compared to Aminosteril plus (\*, p < 0.05). (C) Comparison of different HBG concentrations. Data represent mean ± SEM of Luciferase expression after 24 hours post cmRNA<sup>LUC</sup> (0.5 mg/ml) injection (n ≥ 5). HBG 5% resulted in significant higher expression values (50-fold) compared to 2.5%, 20-fold compared to 10% (\*, p < 0.05) and 4-fold compared to 3.75% (\*, p < 0.05). (D) Comparison of glucose-containing solvents and solutions without glucose. 50 µg cmRNA<sup>LUC</sup> [0.5 mg/ml] was injected in porcine tendon explants 24 hours prior to BLI (n=5). Data represents mean ± SEM of Luciferase expression. Average Luciferase expression values from cmRNA<sup>LUC</sup> formulated in HBG 5% and in NaCl+5%Gluc were significantly higher (20-fold for HBG 5% and 21-fold for NaCl+5%Gluc) compared to isotonic saline solution (\*, p < 0.05). (E) Comparison of carrier systems and isotonic saline. Average luciferase activity with cmRNA<sup>LUC</sup> complexed either with lipid or polymer carriers only reached levels of background expression in bovine as well as ovine tendons. Average expression from 25µg cmRNA<sup>LUC</sup> dissolved in saline solution were 22-fold higher compared to 25 µg cmRNA<sup>LUC</sup> complexed with brPEI (\*, p < 0.05).

### Figure 16

Protein expression in intact and injured rat Achilles tendons *in vivo*. (A) BLI 24 hours after cmRNA<sup>LUC</sup> injection into the intact Achilles tendon. (B) Kinetics and dose-dependency of Luciferase expression in intact Achilles tendons. Luciferin substrate was applied intraperitoneally 15 minutes prior to the measurement (mean ± SEM, n=4) (C) Mean intensity of BMP-7 immunostaining of Achilles tendons at day 1, 2 and 7 post-injury either treated with cmRNA<sup>BMP-7</sup> or vehicle. A trend of increased BMP-7 levels was observed in cmRNA<sup>BMP-7</sup> treated tendons compared to vehicle treated tendons (n ≥ 3). (D) H.E. staining of Achilles tendons at day 1, 2 and 7 post-injury, treated either with cmRNA<sup>BMP-7</sup> or vehicle. Scale bars are equivalent to a length of 400 µm. (E) Mean

intensity of collagen type I immunostaining of Achilles tendons at day 1, 2 and 7 post-injury either treated with cmRNA<sup>BMP-7</sup> or vehicle. Higher intensity at day 2 and at day 7 in cmRNA<sup>BMP-7</sup> treated tendons compared to vehicle treated tendons ( $n \geq 3$ ). (F) Mean intensity of collagen type III immunostaining of Achilles tendons at day 1, 2 and 7 post-injury either treated with cmRNA<sup>BMP-7</sup> or vehicle. Lower collagen type III intensity in cmRNA<sup>BMP-7</sup> treated tendons at day 7 compared to vehicle treated tendons ( $p = 0.057$ ,  $n \geq 3$ ). (G) Ratios of mean intensity of collagen type I to collagen type III immunostaining of Achilles tendons at day 1, 2 and 7 post-injury either treated with cmRNA<sup>BMP-7</sup> or vehicle. Trend towards higher collagen I/III ratios in cmRNA<sup>BMP-7</sup> treated tendons compared to vehicle treated tendons ( $n \geq 3$ ).

### Figure 17

Pathology of collagenase-gel induced tendon defects in sheep. (A-F) Longitudinal (A-C) and transversal (D-F) ultrasound images of a sheep's injured hind limb. (A, D) Longitudinal and transversal ultrasound image at day 0 before collagenase injection, (B, E) 3 and (C, F) 7 days after collagenase-gel injection (100 CDU). (G) Diameter analysis during experimental period of tendons injected with either 100, 200 or 500 CDU and untreated contralateral controls. Data is represented as the mean  $\pm$  SD. Diameter of DDFT increased proceedingly in all groups after collagenase application. (H) External thickness analysis of sheep treated with 100 CDU during experimental period. Data is represented as the mean  $\pm$  SD. External thickness reached maximum (1.5-fold) 4 days post collagenase injection. (I-L) H.E. staining of intact (I, J) and injured (K, L) ovine tendon. (I, J) Typical fiber structure with tenocytes located between fibers. (K) Necrotic material, hematoma, inflammation and massive loss of fiber structure in the central area of the defect. Structure of adjusted fibers was still apparent although fibers were swollen and connections between fibers appeared loosened. (L) Cell number and cell density in surrounded mostly intact areas was increased. (I, K Original magnification  $\times 10$ , J, L Original magnification  $\times 20$ )

### Figure 18

Longitudinal ultrasound image of a sheep's hind limb. Needle was inserted in deep digital flexor tendon before collagenase injection was performed. (SDFT= Superficial Digital Flexor Tendon, DDFT= Deep Digital Flexor Tendon, M.interosseus= Musculus interosseus)

### Figure 19

Successful *in vivo* transfection of injured and intact tendons in sheep. (A, B) Longitudinal (A) and transversal (B) ultrasound image of a damaged DDFT on day 6 with needle inserted in the central part of the tendon. (C) Longitudinal ultrasound image just after SNIM-RNALUC (WO 2011/012316) injection. Injected air is visible in the central area of the tendon. (D, E) BLI of damaged (D) and intact (E) explanted contralateral ovine DDFT 24 hours after *in vivo* injection of 200 $\mu$ g cmRNA<sup>LUC</sup> in each DDFT. Damage was induced by injection of 100 collagen digestion units. BLI was performed within 2 hours post euthanasia. (F, G) H.E. staining of intact cmRNA<sup>LUC</sup> treated tendon at the injection site (F) and 3 cm proximal to the injection site (G). Original magnification  $\times 20$ . (H) White

blood cell (WBC) analysis on day 0, day 6 and day 7. Dashed lines define reference range (5-11 G/l).

#### Figure 20

Defect characterization 7 days after collagenase-gel application containing 200 CDU or 500 CDU (H.E. staining) (A) Hematoma in the central area of the defect. (B) Necrotic material, conglomeration of red blood cells as well as invaded inflammatory cells in peripheral area of the defect. (C) Neovascularization and (D) invasion of inflammatory cells in peripheral area of the hematoma. (E) Red blood cell accumulation between fibers close to the defect and massive inflammation. (F) The contralateral limbs' intact tendon with tenocytes located between parallel fibers. (A-C, E, F original magnification x10, D original magnification x20).

#### Examples

#### Methodology of *ex vivo* experiments (especially pertaining to Examples 1 to 9) Tendon harvest and preparation

**[0047]** Tendon tissue of either slaughtered or euthanized animals were harvested within one hour post mortem and rinsed in ice cold Dulbecco's PBS (1x) containing 1% Penicillin/Streptomycin twice. Deep digital flexor tendons derived from cattle, horses or sheep and Achilles tendons derived from rats or pigs. Connective tissue was removed and major tendons were cut into slices (0.5cm x 3cm).

#### RNA synthesis

**[0048]** A codon optimized DNA sequence (e.g. SEQ ID No. 2) with known flanking sequences was cloned into a standard expression vector for in vitro mRNA production. To generate the template for in vitro transcription, the plasmid was linearized downstream of the poly (A) tail and purified using chloroform extraction and sodium acetate precipitation as described by Sambrook et al. (Sambrook, J., Fritsch, E. F., and Maniatis, T (1989) in Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, N.Y. Vol 1, 2, 3). Complete linearization of plasmid template was confirmed by 1% agarose gel electrophoresis. In vitro transcription was carried out with RiboMAX Large Scale RNA Production System - T7 (Promega, Germany) at 37 °C following the manufacturer's protocol. For in vitro transcription of chemically modified mRNA (cmRNA) 25% cytidine-5'-triphosphate and 25% uridine-5'-Triphosphate were replaced by 5-methylcytidine-5'-triphosphate (TriLink, USA) and 2-thiouridine-5'-triphosphate (TriLink, USA), respectively, in the reaction mixture (for more details see WO 2011/012316). Purification of mRNA was performed by chloroform extraction

and size exclusion chromatography.

### **Ex vivo transfection and cultivation**

**[0049]** mRNA was diluted in different solvents and different concentrations before the injection was performed slowly in parallel direction of the tendon fibers by using a 23G needle for major tendons and 30G insulin syringes for rat Achilles tendons. Transfected tendon slices were stored in tissue culture flasks with vented caps in DMEM (1x) + GlutaMAX medium containing 1% Penicillin/Streptomycin, 2% Nystatin and 10% FBS at 37 °C and 5 % CO<sub>2</sub> immediately after SNIM® -RNA (WO 2011/012316) injection. Four to five samples were stowed per flask.

### **Bioluminescence Measurement**

**[0050]** Firefly Luciferase (FFL) is a common reporter protein that is not endogenously present in mammals and can be detected easily by luminescent imaging. Luciferase catalyses the reaction of luciferin and oxygen which results in bioluminescence emission.

Bioluminescence was measured at indicated time points (24h, 48h, 72h, 168h) using a Xenogen IVIS In-Vivo Imaging System 100 (Caliper Life Science, USA). D-Luciferin substrate diluted in Dulbecco's PBS (1x) was added to the cell culture flasks (100µg D-Luciferin/ml medium) one hour prior to the measurement of luciferase activity. The measurement was operated in the field of view A with high sensitivity (Binning 16) and an exposure time of 1 minute. Living Image® 2.50 software was used for analysis.

### **Betagalactosidase (LacZ) Staining**

**[0051]** Betagalactosidase is another common reporter protein used for analysis of gene expression. The cleavage of Xgal substrate results in a blue precipitate. Tendon slices were injected with 100µg modified LacZ-RNA dissolved in 250µl isotonic saline. LacZ staining was performed 24 hours post injection.

### **BMP7 Immunohistochemistry**

**[0052]** Rat Achilles tendons were injected with 30µg modified BMP-7-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) dissolved in 40µl 1x concentrated HEPES-buffered glucose (HBG, 25mM HEPES, glucose 5% m/v) pH 7.4. After 24 hours of incubation tendons were embedded in Tissue-Tek, deep frozen in liquid nitrogen and stored at - 80°C. Cryosectioning and Immuno-histochemistry were performed by Sophistolab AG (Muttens, Switzerland).

### **Radioisotopic imaging**

**[0053]**  $I^{125}$  marked mRNA was injected into porcine tendon (Pierce Iodination Tubes). Measurement was performed with 1x1 Binning, FOV 10 and an exposure time of 1 min by using an In-Vivo Xtreme BI 4MP, X-ray System (Bruker).

**[0054]** The following Examples 1 to 9 represent *ex vivo* experiments.

**Example 1:** Comparison of bioactivity of naked mRNA with lipid- and polymer-complexed mRNA after injection into bovine and ovine tendon explants. 50  $\mu$ g of naked modified mRNA encoding firefly luciferase (FFL) (25% 2-thiouridine, 25% 5-methylcytidine) was injected into five bovine or ovine tendon explants, respectively, and compared with modified FFL mRNA complexed with DreamFect™ Gold (4 $\mu$ l/1 $\mu$ g RNA, bovine tendon explants) or branched PEI 25kDa (N/P=10, ovine tendon explants). The results of this experiment are shown in Figure 1. Luciferase expression of naked modified FFL mRNA was 295.5-fold higher than for DreamFect™ Gold and 122.5-fold higher than for branched PEI. The results of this experiment are shown in Figure 1.

**Example 2:** Bioactivity of naked mRNA in tendon explants of different species. Modified FFL-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) was injected in tendon explants derived from rats, cattle, sheep, horses and pigs. Either 30 $\mu$ g (rat tendons), 50 $\mu$ g (bovine, ovine and porcine tendons) or 100 $\mu$ g (equine and ovine tendons) of modified FFL-mRNA was injected. The results are shown in Figure 2. Luciferase expression was observed in all different species that had been tested.

**Example 3:** Expression kinetics of different mRNA at different doses.

200 $\mu$ g, 100 $\mu$ g, 50 $\mu$ g, 25 $\mu$ g and 12.5 $\mu$ g modified FFL-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) were dissolved in 250 $\mu$ l isotonic saline. Bioluminescence was measured at determined time points (24h, 48h, 72h, 168h). The results are shown in Figure 3. The highest expression of each dose tested was detected after 24 hours post transfection. Expression decreased during 7 days post transfection.

**Example 4:** Comparison of different solvents used for naked mRNA injection into tendon explants.

50 $\mu$ g modified FFL-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) was dissolved in 200 $\mu$ l (c=0.25mg/ml) of different solvents and injected into five tendon explants per group. The results are shown in Figure 4. The highest Bioluminescence levels after 24 hours were detected when modified FFL-mRNA was dissolved in saline solution compared to other solutions. Significant expression was also observed in Ringer Acetate or Ringer Lactate.

**Example 5:** Comparison of modified FFL-mRNA dissolved in isotonic saline, water for injection and HEPES buffered glucose (HBG 1x).

50 $\mu$ g modified FFL-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) was dissolved in 100 $\mu$ l (c=0.5mg/ml) of HBG pH 7.4 (1x; 25mM HEPES, glucose 5%), isotonic saline and water for injection (WFI) and injected into eight bovine tendon explants. Expression was highest in

HEPES buffered glucose. The results are shown in Figure 5. After 24 hours bioluminescence levels were 6.3-fold higher when modified FFL-mRNA was dissolved in HBG pH 7.4 (1x) compared to modified FFL-mRNA dissolved in isotonic saline and 7.8-fold higher compared to modified FFL-mRNA dissolved in WFI. After 48 hours the expression was 9-fold higher by using HBG pH 7.4 (1x) compared to isotonic saline and 11-fold higher compared to WFI.

**Example 6:** Comparison of different HBG concentrations.

50µg modified FFL-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) was dissolved in 100µl (c=0.5mg/ml) of 0.5x, 0.75x, 1x or 2x concentrated HBG pH 7.4 and was injected into five bovine tendon explants. The results are shown in Figure 6. HBG 1x concentrated resulted in 17.7-fold higher expression compared to 0.5x, 1.4-fold higher compared to 0.75x and 7.3-fold higher compared to 2x after 24 hours and 10.4-fold higher expression compared to 0.75x after 48 hours.

**Example 7:** Comparison of different modified FFL-mRNA amounts.

50µg and 100µg modified FFL-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) were dissolved in 100µl HBG pH 7.4 (1x) and injected into ovine tendon explants. The results are shown in Figure 7. 100µg modified mRNA resulted in 3-fold higher expression after 24 hours, 3.2-fold higher expression after 48 hours and 1.2-fold higher expression after 72 hours compared to 50µg mRNA. Luciferase expression is therefore dose dependent.

**Example 8:** Comparison of different mRNA concentrations.

50µg modified FFL-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) was dissolved in 100µl (c=0.5mg/ml) and in 200µl (c=0.25mg/ml) HBG pH 7.4 (1x) and injected into bovine tendon explants. The results are shown in Figure 8. Increasing the mRNA concentration c=0.5mg/ml resulted in an 5.1-fold higher expression after 24 hours and 21.2-fold higher expression after 48 hours compared to the lower mRNA concentration of c=0.25mg/ml.

**Example 9:** Comparison of different needle sizes that were used for injection in ovine tendon explants.

The injection was performed with either 21G, 23G, 26G, 27G or 30G needles. The results are shown in Figure 9. The highest expression occurred when 100µg (0.25mg/ml) modified FFL-mRNA was injected by using a 23G needle. High expression was also detected with a 30G needle in rat tendons.

[0055] The following Example 10 represents *in vivo* experiments.

[0056] **Example 10:** Luciferase expression in intact and damaged ovine tendons.

### **Methodology of *in vivo* experiments**

#### **Tendon defect induction**

**[0057]** Either 500, 200 or 100 CDU (collagen digestion units) of collagenase type 1A was injected into the deep digital flexor tendons (hind limb) of mature female Merino sheep. The injection was performed under ultrasound guidance.

#### ***In vivo* transfection and tendon harvest**

**[0058]** Six days after the collagenase injection modified FFL-mRNA (25% 2-thiouridine, 25% 5-methylcytidine) diluted in HBG pH 7,4 (1x) was injected into healthy and damaged deep digital flexor tendons. Modified FFL-mRNA (250 µg) was applied in two separate injections of 150 µl (proximal and distal of the defect) under ultrasound guidance.

On the next day tendons were harvested within one hour post euthanasia. Connective tissue and tendon sheath was removed.

#### **Bioluminescence Measurement**

**[0059]** Harvested tendons were immediately incubated in D-luciferin-solution (100µg D-luciferin/ml PBS (1x)) at 37°C and 5% CO<sub>2</sub> for one hour before bioluminescence imaging was performed by using a Xenogen IVIS *In-Vivo* Imaging System 100 (Caliper Life Science, USA) The measurement was operated in the field of view A with high sensitivity (Binning 16) and an exposure time of 1 minute. Living Image® 2.50 software was used for analysis.

The results are shown in Figure 10 a to d. Luciferase expression was detected in intact tendons and in mild, moderate and even severe damaged tendons.

#### **Example 11: LacZ expression in ovine tendons.**

**[0060]** Tendon explants were injected with 100µg modified LacZ-RNA dissolved in 250µl isotonic saline. LacZ staining was performed 24 hours post injection. The cleavage of Xgal substrate results in a blue precipitate. Untreated ovine tendon explants were used as controls. The results are shown in Figure 11A to D.

#### **Example 12: BMP-7 expression in rat tendons.**

**[0061]** Rat Achilles tendons were injected with 30µg chemically modified BMP-7-mRNA (25% 2-thiouridine, 25% 5-methylcytidine; SEQ ID NO. 3) dissolved in 40µl 1x concentrated HEPES-buffered glucose (HBG, 25mM HEPES, glucose 5% m/v) pH 7.4. After 24 hours of incubation tendons were embedded in Tissue-Tek, deep frozen in liquid nitrogen and stored at -80°C. Cryosectioning and BMP-7 immunohistochemistry was performed. The results are shown in

Figure a12 A and B.

### Example 13: Imaging of radioisotopically labeled mRNA

**[0062]**  $^{125}$ I marked mRNA was injected into porcine tendon (Pierce Iodination Tubes). Measurement was performed with 1x1 Binning, FOV 10 and an exposure time of 1 min by using an In-Vivo Xtreme BI 4MP, X-ray System (Bruker) 30 min after injection. The results are shown in Figure 13.

### Further materials and methods (especially pertaining to Examples 14 to 18)

#### *Ex vivo* transfection, cultivation and bioluminescence imaging

**[0063]** Deep Digital Flexor Tendons (DDFT) derived from horses, cattle, sheep or pigs and Achilles tendons derived from rats. Tendons were harvested within one hour after animals had been euthanized (horses, sheep, rats) or slaughtered (pigs and cattle) and rinsed twice in ice cold Dulbecco's phosphate-buffered saline (DPBS) (Life Technologies GmbH Darmstadt, Germany) containing 1% penicillin/streptomycin (PAA Laboratories GmbH Pasching, Austria). Chemically modified naked mRNA either encoding for luciferase (cmRNA<sup>LUC</sup>),  $\beta$ -galactosidase (cmRNA<sup>LacZ</sup>) or human bone morphogenetic protein 7 (cmRNA<sup>BMP-7</sup> (25% 2-thiouridine, 25% 5-methylcytidine); SEQ ID NO. 3) was diluted in different solvents and different concentrations. Injection of cmRNA was performed in parallel direction of tendon fibers using 23G needles (Sterican, B.Braun Melsungen AG, Germany) and 1 ml Injekt-F syringes (B.Braun Melsungen AG, Germany) for major tendons and 30G Insulin syringes (BD Micro-Fine, Becton, Dickinson and Company, Franklin Lakes, USA) for rat Achilles tendons. The cmRNA<sup>LUC</sup> was diluted in different solvents and prepared using commercially available solutions and standard laboratory chemicals (Table 2). Hepes-buffered-glucose (HBG) (Sigma-Aldrich Chemie Schnelldorf, Germany) was adjusted to pH 7.4 and prepared in four different concentrations, namely 2.5%, 3.75%, 5% and 10%. The cmRNA<sup>LacZ</sup> and the cmRNA<sup>BMP-7</sup> were prepared in saline solution only. Complexed cmRNA<sup>LUC</sup> was prepared using Dreamfect™ Gold (OZ Biosciences Marseille, France) as recommended by the manufacturer (10  $\mu$ g cmRNA<sup>LUC</sup>/40  $\mu$ l Dreamfect™ Gold) and using branched polyethyleneimine (brPEI) 25kDa (Sigma-Aldrich Schnelldorf, Germany) at an N/P-ratio of 1:10 using 25  $\mu$ g cmRNA<sup>LUC</sup>.

Transfected tendon specimen were stored in T75 tissue culture flasks (TPP Trasadingen, Switzerland) in 50 ml DMEM (1X) + GlutaMAX medium (Life Technologies Darmstadt, Germany) containing 1% penicillin/streptomycin (PAA Laboratories GmbH Pasching, Austria), 2% nystatin (Sigma-Aldrich Chemie Schnelldorf, Germany) and 10% FBS (Life Technologies Darmstadt, Germany) at 37°C and 5% CO<sub>2</sub> immediately after cmRNA injection.

**[0064]** Bioluminescence imaging (BLI) was conducted at determined points of time, namely 24, 48 and 72 hours after transfection, using a Xenogen IVIS *In-Vivo* Imaging System 100 (Caliper Life Science, USA). D-Luciferin substrate (S039, SYNCHEM, Felsberg/Altenburg, Germany) diluted in Dulbecco's PBS (1X) was added to the cell culture flasks (100µg D-Luciferin/ml medium) one hour prior to the measurement of luciferase activity. The measurement was operated in the field of view A with high sensitivity (Binning 16) and an exposure time of one minute. Living Image® 2.50 software was used for data analysis.

#### **Histological processing of ex vivo cultivated tendon explants**

**[0065]** Staining for  $\beta$ -galactosidase activity was performed 24 hours after the corresponding cmRNA was injected according to the protocol of Dai et al. (Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2003;21:604-9). Tendon specimen were fixed on ice for 30 minutes in 0.5% glutardialdehyde (Carl Roth Karlsruhe, Germany) and 2mM magnesium chloride hexahydrate (Carl Roth Karlsruhe) in DPBS, adjusted to pH 7.4 and subsequently washed twice in rinsing buffer (100mM HEPES, 5mM DTT (Dithiotreitol, Sigma-Aldrich Chemie Schnellendorf, Germany), 1mM MgSO<sub>4</sub> (Magnesium sulfate heptahydrate, Carl Roth Karlsruhe), 2% Triton X-100 (Carl Roth Karlsruhe), pH 8,0) at room temperature for 30 minutes and then rinsed at 50 °C for one hour. Tendon specimen were subsequently incubated in X-Gal staining solution (1mg/ml 5-Bromo-4-Chloro-3-indolyl  $\beta$ , Sigma-Aldrich Chemie), 2mM MgCl<sub>2</sub>, 5mM K<sub>3</sub>Fe(CN)<sub>6</sub> (Potassium ferricyanide (III), Carl Roth Karlsruhe), 5mM K<sub>4</sub>Fe(CN)<sub>6</sub> (Potassium hexacyanoferrate(II) trihydrate, Carl Roth Karlsruhe) in DPBS , pH 7,4) overnight in a non-CO<sub>2</sub> incubator. Finally tendons were fixed in 4% formaldehyde (Roti Histofix, Carl Roth Karlsruhe), dehydrated, embedded in paraffin and counterstained for hematoxylin.

**[0066]** For BMP-7 immunohistochemistry (IHC) tendons were embedded in Tissue-Tek" O.C.T.™ Compound (Sakura Finetek Staufien, Germany), snap frozen in liquid nitrogen and stored at -80°C. Cryosections were prepared and immunohistochemistry was performed by an external laboratory (Sophistolab AG Muttenz, Switzerland) using a rabbit polyclonal BMP-7 antibody (ab56023, abcam plc Cambridge, UK) as primary antibody.

#### ***In vivo* studies in intact and injured rat Achilles tendons**

**[0067]** All experiments were approved by the local ethics committee for animal experiments and adhered to the international guidelines for the care and treatment of laboratory animals. Female Sprague Dawley rats (4 month of age, bodyweight between 300g and 340g, Janvier Labs Saint-Berthevin, France) were group-housed under a 12:12h light-dark cycle with food and water ad libitum. 16 rats were used for Luciferase reporter protein kinetics in intact Achilles tendons and 24 rats were used to test the therapeutic potential of BMP-7 in injured Achilles tendons.

**[0068]** To determine Luciferase reporter protein expression in intact rat Achilles tendons, animals were anesthetized using isoflurane inhalation with air and O<sub>2</sub> as carrier gases (isoflurane 3-5 vol% in an inhalation chamber for induction followed by 1.5-2.5 vol% using an inhalation mask for maintenance). Different doses of cmRNA<sup>LUC</sup> (0, 10, 20, 40µg; dose volume 10µl) were then injected into the right Achilles tendon (n=4 rats/dose group). At day 1, 2 and 7 post cmRNA<sup>LUC</sup> injection *in vivo* bioluminescence imaging was performed using Photon Imager™ (Biospace Lab Nesles la Vallée, France). BLI was conducted 15 minutes after D-Luciferin substrate (L-8220 dissolved in 0.9% saline, Biosynth Staad, Switzerland) was administered intraperitoneally (150mg/kg, 5ml/kg). Images were acquired using 10 minutes of integration time. No filter was used. Quantification was performed using a region of interest defined manually (Achilles tendon) and the results were expressed as total counts. M<sup>3</sup>Vision software (Biospace Lab, Nesles la Vallée, France) was used for data analysis. On day 7, rats were sacrificed with CO<sub>2</sub>, Achilles tendons were explanted immediately and Luciferase activity was measured again in tendon explants.

**[0069]** Therapeutic cmRNA<sup>BMP-7</sup> (25% 2-thiouridine, 25% 5-methylcytidine; SEQ ID NO. 3) was applied directly into injured, i.e. dissected and surgically repaired Achilles tendons to investigate the influence on early tendon healing. Prior to surgery rats received a subcutaneous (sc.) injection of 0.05 mg/kg buprenorphine (Temgesic®, Reckitt Benckiser Wallisellen, Switzerland). Surgery was performed under inhalation anesthesia as described above. The left leg was prepared for aseptic surgery and then fixed in a custom-made holder to stabilize the ankle at a 90° position with the foot facing downwards. An incision was made above the left Achilles tendon. The superficial Achilles tendon was exposed and was fully dissected in the midportion between the calcaneus side and the muscle insertion. The Plantaris tendon was left intact. An end-to-end anastomosis of the Achilles tendon stumps was then performed applying a Three Loop Pulley pattern suture using a non-absorbable monofilament (Prolene® 5-0, 3/8 reverse cutting needle P3, Ethicon, Johnson & Johnson Medical, Norderstedt, Germany). Subsequently, either cmRNA<sup>BMP-7</sup> (100µg;) or vehicle was administered intra-tendinously proximal and distal to the anastomosis with a dose volume per injection site of 5 µl (BD Micro-Fine 30G Insulin Syringes, Becton, Dickenson and Company, Franklin Lakes, USA). The subcutaneous layer and the skin were then closed by a continuous suture technique with an interrupted intracutaneous suture using an absorbable synthetic thread (Safil® 6-0, B. Braun Melsungen AG, Germany). Animals were then allowed to wake up on a heating pad to aid the return to normal body temperature. Buprenorphine was again administered every 8-12h post-surgery for up to two days.

**[0070]** On day 1, 2, and 7 post-surgery each 4 cmRNA<sup>BMP-7</sup>-treated and 4 vehicle-treated rats were sacrificed with CO<sub>2</sub> and both injured and intact contralateral Achilles tendons were explanted. Achilles tendons were fixed overnight in 4% paraformaldehyde (Sigma-Aldrich Chemie Buchs, Switzerland), dehydrated with an ascending ethanol series, and embedded in paraffin (Paraplast Xtra, Leica Wetzlar, Germany). For immunohistochemistry Anti-BMP-7 antibody (ab56023, abcam plc Cambridge, UK), polyclonal Anti-Collagen I antibody (ab 34710,

abcam plc Cambridge, UK) and polyclonal Anti-Collagen III antibody (ab7778, abcam plc Cambridge, UK) were used as primary antibodies. Biotinylated Goat Anti-Rabbit IgG (BA-1000, Vector Laboratories, Peterborough, UK) were used as secondary antibodies. Staining was induced by peroxidase (biotin-labeled) activity. Sections were counterstained with hematoxylin (VWR International, Dietikon, Switzerland). DAB staining in microscopic images was thresholded and mean gray values of positive pixels were evaluated. Analysis was performed with Fiji/Image J Version 1.49k.

### ***In vivo* studies in an ovine model of acute tendon injury**

**[0071]** All experiments were approved by the local ethics committee for animal experiments and adhered to the international guidelines for the care and treatment of laboratory animals. For large animal experiments, nine female mature Merino sheep, 4-7 years of age, bearing between 72 kg and 87 kg, were group housed under a 12:12-h light-dark cycle. Hay and water was provided ad libitum. All large animals had no clinical or ultrasonographic evidence of tendon injury.

**[0072]** For tendon defect induction a collagenase-gel model was chosen (Watts, Equine veterinary journal. 2012;44:576-86; Smith, Equine veterinary journal. 2014;46:4-9). The metatarsal area of both hind limbs was clipped, shaved and aseptically prepared before either 500, 200 or 100 collagen digestion units (CDU) of collagenase type 1A (from *Clostridium histolyticum* C0130, Sigma-Aldrich Chemie Schnellendorf, Germany) were injected into the Deep Digital Flexor Tendon (DDFT) of the left hind limb. Collagenase was diluted in Dulbecco's PBS (1X), filter sterilized and merged with 50 µl of thrombin solution (Component 2, Tissucol Duo S Immuno, Baxter Unterschleißheim, Germany). The injection was performed with a lateral approach in the mid-tarsal area under ultrasound guidance (Mindray DP 50 vet; Sonoring Schmitt-Haverkamp, Germany) using a 23 gauge needle and a Duploject system (Baxter Germany) in which the collagenase-thrombin-solution was combined with 50 µl fibrinogen-solution (Component 1, Tissucol Duo S Immuno, Baxter Germany) during injection. Fig. 18 shows a longitudinal ultrasound image of a sheep's hind limb while the needle was inserted in DDFT just before the injection was performed. Ensuring that the gel formation process had been completed, the needle was not withdrawn until 30 seconds had passed after injection. A suture was applied where the needle was inserted.

**[0073]** Antibiotics (Veracin® compositum 3 ml/50kg, Albrecht, Aulendorf, Germany) were administered intramuscularly every second day for five days. 0.3 mg Buprenorphin-hydrochloride (Buprenovet® Multidose 0.3 mg/ml, Bayer HealthCare, Leverkusen, Germany) was applied subcutaneously every twelve hours for two days and Ketoprofen 3 mg/kg (Romefen® PR 10%, Merial, Hallbergmoos, Germany) every twenty-four hours for five days as analgesics. Frequent ultrasound and daily clinical examination was performed by two veterinarians. A portable Mindray DP 50 vet ultrasound machine (Sonoring Schmitt-Haverkamp, Germany) with a linear probe (5-12 MHz) was used. Ultrasound examinations were performed with the sheep bearing weight on the examined foot. Diameter of the DDFT

was measured in the mid-tarsal area, 2cm below the applied suture. External thickness was measured from medial to lateral in the same mid-tarsal area by using a digital caliper in group treated with 100 CDU.

**[0074]** Six days after collagenase injection, cmRNA<sup>LUC</sup> diluted in HBG 5% was injected into healthy and damaged deep digital flexor tendons of both hind limbs. Procedure was again performed under general anesthesia. The cmRNA<sup>LUC</sup> was applied in two separate injections of 100 µg (500 CDU group, n=2), 200 µg (200 CDU group, n=2) or 250 µg (100 CDU group, n=2) cmRNA (proximal and distal area of the defect) under ultrasound guidance. Some air was drawn in the syringe and injected in the end of the injection to ensure that syringe and needle were emptied completely. Ketoprofen 3 mg/kg (Romefen® PR 10%) was administered intravenously during anesthesia.

**[0075]** On the next day, the sheep were euthanized by an intravenous overdose of pentobarbital (Euthadorm®, CP-Pharma, Burgdorf, Germany) and tendons were harvested within one hour post euthanasia. Connective tissue and tendon sheath was removed. Harvested tendons were immediately incubated in D-Luciferin-solution (100 µg D-Luciferin/ml PBS (1x)) at 37°C and 5% CO<sub>2</sub> for one hour before bioluminescence imaging was performed by using a Xenogen IVIS *in-vivo* Imaging System 100 (Caliper Life Science, USA). The measurement was operated in the field of view A with high sensitivity (Binning 16) and an exposure time of one minute. Living Image® 2.50 software was used for the analysis. Tendons were fixed in 4% paraformaldehyde for 24 hours, dehydrated with an ascending ethanol series, and embedded in paraffin. In intact tendons five parts of cmRNA<sup>LUC</sup> injected area were chosen, as well as parts 3cm proximal and distal to the injection site. In injured tendons central and peripheral areas of the defect were selected. 3 µm sections were stained with hematoxylin and eosin for histopathological examination.

**[0076]** Blood was taken on day 0, day 6 (before mRNA application) and day 7 (before euthanasia) and full blood count as well as liver and kidney test values were analyzed by an external veterinary laboratory.

### **Statistical analysis**

**[0077]** All statistical analyses were performed with GraphPad Prism 5. Results are presented as the mean ± SEM, with n equal to the number of samples per group. Differences between groups were analyzed for significance using Mann Whitney U test, with significance attained at  $p < 0.05$ . Results in Fig. 17G, H and Tab. 3 are presented as the mean ± SD.

### **Example 14: Injection of naked cmRNA results in high protein expression in tendon explants**

[0078] Naked cmRNA dissolved in saline solution was injected into tendon explants to investigate, whether chemically modified messenger RNAs could transfect tendon tissue thereby resulting in the expression of therapeutic protein(s). An initial *ex vivo* experiment was conducted in explanted porcine tendons. Tendon tissue was transfected through direct injection of cmRNA<sup>LUC</sup> following which, the explants were then incubated (24 hours, 37° C, 5% CO<sub>2</sub>) and luciferase activity was measured subsequently. Using this methodology, Luciferase expression was detected in specimen injected with cmRNA<sup>LUC</sup>, but not in untreated control tendons or in tendons injected with saline solution only. Based on these promising findings, further experiments were conducted in explants of different animal species to investigate, whether the concept of *ex vivo* transfection could be successfully applied to more mammals. Interestingly, besides expression in porcine tendon explants, injection of naked cmRNA<sup>LUC</sup> resulted also in distinct Luciferase expression in explanted tendons of sheep, cattle, horses, and rats (Fig. 14A). Notably expression patterns revealed a particular distribution with highest Luciferase activity at the injection site and a slim, tube-like distribution within the entire explant.

[0079] In a next set of experiments, dose-dependent expression of Luciferase could be demonstrated in porcine tendons after injection of cmRNA<sup>LUC</sup> (Fig 14B). Luciferase expression directly correlated with the amount of injected mRNA and was 10-fold higher at a used cmRNA<sup>LUC</sup> amount of 200µg compared to 25µg (Fig. 14B). To identify the transfected cells, cmRNA encoding for β-galactosidase was injected into porcine tendon explants and tissues stained for β-gal activity at 24 hours after incubation. Similar to luciferase expression, most of the β-gal expression was localized both in tenocytes and connective tissue cells close to the injection site (Fig. 14D, 14F). In control tendons injected with cmRNA<sup>LUC</sup> no positive β-gal staining could be observed (Fig. 14E, 14G).

[0080] Encouraging results with reporter genes (Luciferase and β-galactosidase) prompted us to investigate the applicability of this technology to produce therapeutic proteins. Human BMP-7 was selected as a therapeutic target, as its potential to increase healing processes due to stimulating effects on tenocytes has been discussed recently (Yeh, Journal of cellular biochemistry. 2008;104:2107-22; Pauly, Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons. 2012;21:464-73). Further *in vivo* experiments were intended to be conducted in rats, hence cmRNA encoding for human BMP-7 was injected into rat Achilles tendons and BMP-7 immunohistochemistry (IHC) was performed after a cultivation period of 24 hours. Using this methodology, BMP-7 positive signals were found in vascular walls, connective tissue and tenocytes in BMP-7 transfected tendon specimen (Fig. 14H, J). Indeed control specimen revealed to be slightly positive as well, but merely in vascular walls (Fig. 14I, K).

#### **Example 15: Glucose enhances, amino-acids impair Luciferase expression in tendon explants**

[0081] As initial experiments showed strongest expression in bovine tendon tissue it was

continued by using bovine tendon explants for further experiments. Investigating expression kinetics, peak expression after 24 hours and clear drop off (2-fold) after 48 hours were observed. At 72 hours post injection, luciferase expression reduced to almost background levels (Fig. 15A).

It was further investigated if tendon transfection and transgene expression could be further potentiated via use of different commercially available and/or standard laboratory solutions containing amino acids, electrolytes and/or sugars. It was hypothesized that (1) osmotic gradients may increase intracellular electrolyte influx and thereby intracellular uptake of cmRNA, (2) providing cells with additional amino acids may enhance the translation of cmRNA, (3) precipitating mRNA with ammonium acetate may result in a "depot effect" thereby enabling relatively long-term expression. Furthermore, colloidal solutions were used to test the influence of large molecules on transfection of tendon tissue. As highest expression levels were observed 24 hours after cmRNA<sup>LUC</sup> injection, this point of time was selected for the comparison of different solvents.

**[0082]** Our results indeed reveal strong influence of the used solvent/electrolyte on the resulting Luciferase expression. This effect was most prominent when comparing electrolyte and/or glucose-containing solutions with solutions containing amino-acids (Fig. 15B). Noticeably, glucose-containing solution such as HEPES buffer containing 5% glucose (HBG 5%) resulted in highest Luciferase expression compared to saline solution (15-fold,  $P < 0.05$ ) or amino-acids-containing solution (57-fold compared to Aminosteril plus,  $p < 0.05$ ). cmRNA<sup>LUC</sup> in ammonium acetate solution completely abolished the expression of luciferase. Reasoning, whether concentration of glucose influences transfection efficacy, highest Luciferase expression was observed at a glucose concentration of 5% and which decreased several fold when glucose concentration was either increased (20-fold less) or decreased (50-fold) (Fig. 15 C). To verify that these findings were transferable to other species, experiments in porcine tendons were continued. It was further examined, whether mixing of glucose and saline may additionally enhance transfection efficacy. Mixing 5% glucose with saline (NaCl+5%Gluc) did not affect Luciferase expression compared to HBG 5% solution (Fig. 15D).

**[0083]** As mRNA application was recently used to be conducted with mRNA formulated in carrier systems, transfection efficacy of cmRNA<sup>LUC</sup> complexed with lipid and polymer carriers in different species was furthermore examined. Interestingly, cmRNA<sup>LUC</sup> complexed with DreamFect Gold resulted in expression levels only comparable to w/t specimen. Moreover, Luciferase expression was 22-fold lower in tendons treated with cmRNA<sup>LUC</sup> complexed with brPEI compared to cmRNA<sup>LUC</sup> dissolved in saline solution.

**Example 16: Naked chemically modified mRNA efficiently transfects intact rat Achilles tendons *in vivo***

**[0084]** To test the translation of our *ex vivo* findings in vivo cmRNA<sup>LUC</sup> dissolved in the best

performing solution (HBG containing 5% glucose, adjusted to a pH of 7.4) was injected into Achilles tendons of rats at 4 different doses (40, 20, 10 and 0  $\mu\text{g}$ ). Expression of Luciferase protein was measured by *in vivo* BLI at 1, 2 and 7 days post injection (Fig. 16A). Dose-dependent Luciferase expression was also observed in rat Achilles tendons *in vivo* and expression kinetics were comparable with the *ex vivo* data in porcine tendons (Fig 14B) and bovine tendons (Fig 15A). Highest expression was observed at 24 hours post cmRNA injection which declined over time to extremely low but detectable levels by day 7 (Fig. 16B).

**Example 17: Naked cmRNABMP-7 positively affects early healing in injured rat Achilles tendons *in vivo***

**[0085]** The therapeutic potential of human BMP-7 was investigated in rats on the healing of dissected and surgically repaired Achilles tendons. Histological examination of healing Achilles tendons was performed 1, 2 and 7 days after surgery and injection of mRNA<sup>BMP-7</sup> (25% 2-thiouridine, 25% 5-methylcytidine; SEQ ID NO. 3) or vehicle (HBG 5%).

**[0086]** Tendon samples were stained for BMP-7 using immunohistochemistry (IHC) to evaluate, whether mRNA<sup>BMP-7</sup> injection induced the expression of therapeutic protein. Compared to untreated intact contralateral Achilles tendons, BMP-7 expression increased in all tendons that underwent surgical procedure from day 1 until the end of the study at day 7, no matter whether they received cmRNA<sup>BMP-7</sup> or vehicle. However, BMP-7 expression levels were higher during the whole experimental period in cmRNA<sup>BMP-7</sup>-treated tendons compared to vehicle-treated tendons (Fig. 16C).

At day 1 post-surgery histopathological examination of the injured Achilles tendon revealed an inflammatory reaction with immigration of granulocytes and more or less necrotic areas with or without hematoma in both groups. Increased mitotic activity of tenocytes and fibroblasts was observed in both groups, indeed more distinct in animals being treated with cmRNA<sup>BMP-7</sup>. At day 2 post-surgery comparable increase in inflammation and tissue proliferation was apparent in both groups. At day 7 post-surgery further proliferative progress was apparent, however all samples exhibited fibrous "bridge-like" tissue in the anastomosis region (Fig. 16D, E).

**[0087]** Analysis of IHC for collagen type I revealed a slight decrease in expression from day 1 to day 2 in tendons being treated with vehicle, whereas mean intensity in tendons treated with cmRNA<sup>BMP-7</sup> remained stable. The decrease was followed by a very slight increase until day 7 in both groups. At day 2 and day 7 the intensity of collagen type I was thereby higher in tendons treated with cmRNA<sup>BMP-7</sup> compared to tendons treated with vehicle only (Fig. 16E). In contrast, the expression of collagen type III decreased from day 1 to day 2 in both groups, but more distinct in the cmRNA<sup>BMP-7</sup> group, followed by a pronounced increase in the vehicle group from day 2 to day 7. At day 7 the signal intensity for collagen type III was considerably lower in tendons treated with cmRNA<sup>BMP-7</sup> than in vehicle-treated tendons ( $p = 0.057$ ) (Fig.

16F). Additionally, collagen type I to collagen type III ratios of tendons treated with  $\text{cmRNA}^{\text{BMP-7}}$  were higher at day 2 and at day 7 compared to the vehicle group (Fig. 16G).

**Example: 18: Naked cmRNA efficiently transfects injured and intact tendons in large animals *in vivo***

**[0088]** Tendinopathy is characterized by matrix disorganization, hypercellularity, fiber disorientation and vascular ingrowth. As these conditions could not be compared to those of intact or surgically injured tendons, cmRNA's capability of transfecting tendons in a large animal model of tendinopathy was ought to investigate. Collagenase-gel in three different doses (100 CDU, 200 CDU, 500 CDU) was therefore injected into the left Deep Digital Flexor Tendon (DDFT) of anesthetized elderly sheep to generate a defect with partial failure, resembling clinical characteristics of preliminary stages of tendinopathies in humans and horses. Subsequent clinical and ultrasound examination was performed at different time-points (Fig. 17A-F). Ultrasound examination furthermore revealed increasing inhomogeneity in all groups. Diameter of DDFTs treated with 100 CDU increased 1.57-fold from  $0.44 \text{ cm} \pm 0.030 \text{ cm}$  to  $0.69 \text{ cm} \pm 0.126 \text{ cm}$  within 2 days and to  $0.74 \text{ cm} \pm 0.150 \text{ cm}$  at day 7 (Fig. 17G). DDFTs' diameter of sheep treated with 200 CDU and 500 CDU increased even stronger, with peaking size on day 6 ( $1.01 \text{ cm} \pm 0.0566 \text{ cm}$  for 200 CDU,  $1.04 \text{ cm} \pm 0.099 \text{ cm}$  for 500 CDU). Due to our pain treatment, only slight lameness was objected in sheep treated with 100 CDU within the first three days after collagenase-gel injection. However, the limbs' external thickness increased 1.5-fold within 4 days from  $1.47 \text{ cm} \pm 0.351 \text{ cm}$  to  $2.23 \text{ cm} \pm 0.493 \text{ cm}$ , but consistently decreased again to  $1.87 \text{ cm} \pm 0.462 \text{ cm}$  at day 7 (Fig. 17H). Sheep treated with 200 CDU or 500 CDU suffered from moderate lameness within four days post collagenase injection and from slight lameness until day 7.

Tendon defects were investigated histologically at day 7 (animals euthanized on this day), revealing smaller necrotic areas with loss of fiber structure, conglomerations of red blood cells and some invading inflammatory cells in the central area of the defect (Fig. 17K) as well as smaller conglomerations of red blood cells and isolated inflammatory cells between tendon fibers in the adjacent area of the defect in tendons treated with 100 CDU. Moreover, adjacent fibers seemed swollen and connections between fibers appeared loosened. Cell number and cell density were increased (Fig. 17I) compared to intact tendons (Fig. 17L). Tendons injected with 200 CDU and 500 CDU were characterized by large-area necrosis and hematoma with immense loss of fiber structure. Moreover, massive invasion of inflammatory cells could be objected (Fig. 18). Necrotic area in tendons injected with 500 CDU were extended to one third of the tendon, in tendons injected with 200 CDU around one quarter of the tendon was affected.

**[0089]** At day 6, i.e. 24 hours before euthanasia,  $\text{cmRNA}^{\text{LUC}}$  (500  $\mu\text{g}$  in 100 CDU group, 400 $\mu\text{g}$  in 200 CDU group and 200 $\mu\text{g}$  in 500 CDU group) was injected into the defect of the left injured (Fig. 19A, B) and into the right intact tendon under ultrasound guidance. Injected air that had been withdrawn in the syringe together with  $\text{cmRNA}^{\text{LUC}}$  made the application position visible by

ultrasound (Fig. 17C). One day later sheep were euthanized and tendons were harvested for *ex vivo* BLI and histopathological examination. Luciferase expression was more widely distributed and intensive in the injured region than in healthy tissue of the contralateral tendon (Fig. 19D, E). The histopathological examination of cmRNA<sup>LUC</sup> treated intact tendons showed predominantly intact tendon tissue without pathological findings. Only a few small cellular conglomerations of macrophages and granulocytes could be detected (Fig. 19F). Tissue distal and proximal of the injection site was without any abnormalities (Fig. 19G). Lameness or tissue swelling could not be detected.

**[0090]** With regard to side-effects it has to be mentioned, that animals were clinically examined every day. No adverse effects became apparent due to the application of cmRNA. Furthermore, blood analysis was performed before and 24 hours after the application of cmRNA. Indeed no pathological changes became apparent and measured values of blood leucocytes were within the physiological range after mRNA application (Fig. 19H). Additionally full blood count, liver and kidney test values were analyzed (Fig. 20). No pathological findings due to cmRNA application could be identified.

#### **Example 19: Further discussion, especially of Examples 14 to 18**

**[0091]** Tendon injuries or degenerative tendinopathies are common in both animals and humans, especially in athletes (Kvist, Sports medicine (Auckland, NZ). 1994;18:173-201). Achilles tendon and rotator cuff tendinopathies, for example, are frequently diagnosed among humans (Jarvinen, Foot and ankle clinics. 2005;10:255-66, Herrmann, Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca. 2014;81:256-66). The appearance of tendon damage is various. The occurrence is heterogenous and ranges from acute rupture to chronic tendinopathies. Medical reasons are multisided and predisposal factors are similar in humans and animals, such as overloading due to training or joint malposition, age, gender, genetics, body weight or endocrinopathies (Patterson-Kane, ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 2014;55:86-99, Perkins, New Zealand veterinary journal. 2005;53:184-92, Baird, Connective tissue research. 2014;55:275-81, Ippolito, Italian journal of orthopaedics and traumatology. 1975;1:133-9, Magnan, Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons. 2014;20:154-9). In numerous cases chronic damage caused by overuse or degenerative processes leads to an acute injury or even tendon rupture (Jarvinen, Scandinavian journal of medicine & science in sports. 1997;7:86-95). Beside degenerative processes, a failed healing after tendon injury is also discussed as pathogenesis of tendinopathies (Rees, The American journal of sports medicine. 2009;37:1855-67, Watts, Equine veterinary journal. 2012;44:576-86).

**[0092]** The natural healing potential of tendon tissue is low due to hypocellularity, hypovascularity and a low metabolic rate compared to other soft tissues (Bray, Journal of anatomy. 1996;188 (Pt 1):87-95, Sharma, Journal of musculoskeletal & neuronal interactions. 2006;6:181-90, Liu, Tissue engineering Part B, Reviews. 2011;17:165-76). The healing

process is therefore extremely slow (James, *The Journal of hand surgery*. 2008;33:102-12, Williams, *Sports medicine (Auckland, NZ)*. 1986;3:114-35); it usually takes months or years. The healing process moreover normally results only in tissue repair instead of regeneration as the original tensile strength and elasticity is usually not regained (Sharma, *Foot and ankle clinics*. 2005;10:383-97). Recovery is therefore rarely fully functional (Sharma, *Journal of musculoskeletal & neuronal interactions*. 2006;6:181-90, Hogan, *The Journal of the American Academy of Orthopaedic Surgeons*. 2011;19:134-42) and the risk of re-injury or even a tendon rupture is highly increased (Mast, *The Surgical clinics of North America*. 1997;77:529-47).

Treatment methods are numerous and can be categorized in conservative and surgical therapy. Besides rest and bandaging followed by controlled exercise in cases of acute injury, conservative therapy methods can also be intra lesion application of various substances such as corticosteroids (Muto, *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2014;32:1297-304, Hart, *Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine*. 2011;21:540-1), which is highly controversial; hyaluronic acid (Muneta, *Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association*. 2012;17:425-31, Foland, *American journal of veterinary research*. 1992;53:2371-6) or glycosaminoglycans (Moraes, *The Veterinary record*. 2009;165:203-5) that are components of the extracellular matrix in tendons. Furthermore, physical methods such as electromagnetic stimulation or shockwave therapy (Bosch, *Equine veterinary journal*. 2007;39:226-31, Seeliger, *European journal of medical research*. 2014;19:37) are used. Also various approaches using stem cell-based (Smith, *Disability and rehabilitation*. 2008;30:1752-8, Martinello, *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2013;31:306-14, Renzi, *Research in veterinary science*. 2013;95:272-7) and growth factor-based therapies are investigated (Witte, *Journal of the American Veterinary Medical Association*. 2011;239:992-7, Shah, *Journal of orthopaedic research: official publication of the Orthopaedic Research Society*. 2013;31:413-20, Arguelles, *The Veterinary record*. 2008;162:208-11, de Vos, *British journal of sports medicine*. 2011;45:387-92).

The assumption that cytokines and growth factors play a key role during the healing process generated considerable research interest in growth-factor based gene therapy, namely that they stimulate cell proliferation as well as cell differentiation and formation of extracellular matrix components (Molloy, *Sports medicine (Auckland, NZ)*. 2003;33:381-94, Evans, *Sports medicine (Auckland, NZ)*. 1999;28:71-6, Grotendorst, *International journal of tissue reactions*. 1988;10:337-44). Various *ex vivo* and *in vivo* experiments provided promising results, for example improved tendon healing in a rat Achilles tendon healing model after BMP-12 gene transfer (Majewski, *Gene therapy*. 2008;15:1139-46) or a positive influence of platelet-rich plasma on core lesions of Superficial Digital Flexor Tendons (SDFT) in horses (Bosch, *Journal of orthopaedic research: official publication of the Orthopaedic Research Society*. 2010;28:211-7). In recent years much research has been focused on DNA gene transfer in the field of growth factor based therapies (Majewski, *Gene therapy*. 2008;15:1139-46, Nakamura, *Gene therapy*. 1998;5:1165-70, Evans, *International orthopaedics*. 2014, Lou, *Journal of orthopaedic research: official publication of the Orthopaedic Research Society*. 2001;19:1199-202), which are not very efficient due to limitations of nuclear entry in non-dividing cells (Tong, *Current gene therapy*. 2009;9:495-502), and carry potential risk of mutagenesis. Messenger RNA on

the other hand has been successfully applied in several mouse models. Kormann et al. reported raising hematocrit levels after single intramuscular injection of modified murine erythropoietin encoding mRNA and in addition, aerosol application containing surfactant B protein encoding mRNA in a congenital mouse disease model reconditioned large parts of the lung (Kormann, Nature biotechnology. 2011;29:154-7). Furthermore, human VEGF encoding modified mRNA improved heart function and long-term survival in a mouse model of myocardial infarction (Zangi, Nature biotechnology. 2013;31:898-907). In the context of the invention a focus was set on application of chemically modified naked mRNA (cmRNA) in intact as well as in surgically and chemically injured tendons.

**[0093]** Chemically modified mRNAs represent a novel platform technology for transfecting tissues and consequently expressing therapeutic proteins within the body for the treatment of various pathological conditions (Kormann, Nature biotechnology. 2011;29:154-7, Zangi, Nature biotechnology. 2013;31:898-907). It is reported herein for the first time that there is feasibility of using cmRNA technology as a therapeutic approach for effective expression of physiologically active proteins in intact and injured tendons. A self established *ex vivo* transfection method enabled us to screen transfection efficacy of cmRNA in a variety of species (sheep, cattle, horses, hogs and rats), to optimize transfection conditions and to evaluate expression of several proteins (Luciferase,  $\beta$ -Galactosidase and BMP-7) in a cost efficient and rapid manner. Reporter protein expression was species independent and expression levels were significantly higher when naked cmRNA was applied compared to cmRNA complexed with common lipid and polymer carriers. Furthermore, transgene expression could be optimized when using naked mRNA dissolved in glucose-containing solvents, which could possibly be explained by nutrition effects as tendons are poorly provided with blood due to the low incidence of blood vessels.

**[0094]** Results of our *ex vivo* studies were confirmed *in vivo* in intact rat Achilles tendons and subsequently in a Achilles tendon injury model of dissected and surgically repaired Achilles tendons in rats as well as in a collagenase-gel induced tendon defect model in sheep. Injection of cmRNA<sup>LUC</sup> into healthy tendons resulted in considerable Luciferase expression, peaking after 24 hours and fading out within 7 days in a dose-dependent manner. These observations resembled expression kinetics observed in our *ex vivo* studies. Injection of cmRNA<sup>BMP-7</sup> into injured Achilles tendons in turn, resulted in a BMP-7 expression pattern with proceedingly increasing BMP-7 levels up to day 7. Additionally certain background expression of BMP-7 was detected in healthy rat tendons *ex vivo* and *in vivo*, as the antibody used cross reacted with endogenous rat BMP-7. Furthermore, expression of endogenous BMP-7 was strongly increased, due to the surgical procedure during rat Achilles tenotomy. Indeed increased expression of BMP-7 as a consequence to harming insults on tendons has already been described by others in various animal studies and patient derived tissue specimen of tendinopathic tendons (Eliasson, Clinical orthopaedics and related research. 2008;466:1592-7, Yee, Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2011;29:816-21, Rui, Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2012;20:1409-17, Yu, Arthroscopy: the journal of arthroscopic & related surgery: official publication of the Arthroscopy Association of North America and the International

Arthroscopy Association. 2007;23:205-10, Lui, BMC musculoskeletal disorders. 2013;14:248). However, a trend of increased BMP-7 expression was observed in tendons being treated with cmRNA<sup>BMP-7</sup> compared to tendons being treated with vehicle at all points of time after injury. Therefore it was reasoned that injecting cmRNA<sup>BMP-7</sup> can contribute to increased and prolonged BMP-7 expression in injured tendons.

**[0095]** Increased catabolism of collagen type I is considered to be a critical parameter in the inflammatory and early proliferative phase (day 1 to day 7 post injury) of tendon healing, though strong decrease of collagen type I is suspected to be associated with increased formation of non-functional scar tissue, instead of functional tendon tissue (Sharma, The surgeon: journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2005;3:309-16, Loiselle, PloS one. 2012;7:e40602). In contrast, collagen type III is associated with characteristics of scar-like tissue, namely loss of tensile strength and elasticity compared to intact tendon tissue (Sharma, Foot and ankle clinics. 2005;10:383-97). A preferably small content of collagen type III is therefore desirable. In our present study, a tendency of collagen type I catabolism in the vehicle group until day 2 post-surgery was detected, whereas the collagen type I content in tendons being treated with cmRNA<sup>BMP-7</sup> remained stable during the whole experiment. A strong increase in collagen type III content was observed in the vehicle group from day 2 to day 7 post-surgery, while in tendons being treated with cmRNA<sup>BMP-7</sup> the increase was less prominent. Consequently, a trend towards a higher ratio of collagen type I to collagen type III was detected in cmRNA<sup>BMP-7</sup> treated tendons. The histopathological assessment revealed an increased cellular infiltration in cmRNA<sup>BMP-7</sup> treated animals at day 1 post injury. However no differences regarding inflammation and callus formation became apparent after day 2 and day 7.

**[0096]** Taking these findings together, cmRNA<sup>BMP-7</sup>-induced expression of physiologically functional BMP-7 protein apparently supports tendon healing, through more cellular infiltration and less fulminant collagen III formation. In principle, our present results provide insights into the early healing phase of acute Achilles tendon injury in rats. However, long term studies could be conducted to further clarify, whether cmRNA<sup>BMP-7</sup> intervention at early time points would be beneficial in all phases of the entire healing process. Although opinions might be discordant as to the question whether BMP-7 enhances tendon healing or impairs it by inducing heterotopic ossification or cartilage formation (Yeh, Journal of cellular biochemistry. 2008;104:2107-22, Yee, Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2011;29:816-21, Forslund, Acta orthopaedica Scandinavica. 1998;69:622-6, Lui, Rheumatology (Oxford, England). 2013;52:2116-26), the findings provided herein suggest that overexpression of BMP-7 during the inflammatory phase of tendon regeneration positively influences healing, due to chemotactic attraction of cells, less pronounced collagen type I degradation and decreased collagen type III formation.

**[0097]** Tendon rupture can occur spontaneously, and patients might not have suffered from symptoms before (Kvist, Sports medicine (Auckland, NZ). 1994;18:173-201, Jozsa,

Champaign, Illinois: Human Kinetics; 1997). Degenerative processes are thought to be responsible, which may lead to an altered structure in tendinopathic tissue compared to intact tendons (Riley, Matrix biology : journal of the International Society for Matrix Biology. 2002;21:185-95). Transformed tissue is characterized by disintegration of collagen fibers, loss of matrix organization and at most mild inflammatory processes in chronic stages (Pecina, Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca. 2010;77:277-83). One explanation for this kind of degeneration might be an upregulation of collagenolytic enzymes, such as specific matrix metalloproteinases (MMPs), as it has been detected in chronically altered tendinopathic tendons of humans and animals (Castagna, Muscles, ligaments and tendons journal. 2013;3:132-8, Jones, Arthritis and rheumatism. 2006;54:832-42, Muir, Veterinary Surgery. 2005;34:482-90, Nomura, J Vet Med Sci. 2007;69:637-9). Similar MMP expression patterns had also been observed in experimentally affected tendons by collagenase-gel injection in horses (Watts, Equine veterinary journal. 2012;44:576-86). However, in human and veterinary medicine, patients are often presented with symptoms such as pain and discomfort, at a clinical stage before tendons are ruptured. In cases of overuse this symptoms probably result from microtraumatic fiber disruption and subsequent inflammation (Kannus, Scandinavian journal of medicine & science in sports. 1997;7:78-85). Based on these assumptions a defect model with partial failure could be generated with injection of 100 CDU, imitating clinical characteristics of preliminary stages of tendinopathies in humans and horses. It has to be mentioned that defects induced by 200 CDU or 500 CDU caused a detrimental pathology, which is not considered to represent the clinical situation.

**[0098]** From the herein disclosed *ex vivo* experiments using  $\beta$ -galactosidase encoding cmRNA it can be seen that transgene expression is distributed tube-like, within fibrils in healthy specimen. Thus it was reasoned, whether this distribution pattern would be the same in pathologically altered tendons, with disintegrated fiber structure due to prior collagenase injection. To clarify this question, cmRNA<sup>LUC</sup> was injected into injured regions of tendons in a highly translational sheep model of tendonitis. Indeed it was observed in tendons treated with 100 CDU, that transfection efficacy in injured tendons reached equal levels as in intact tendons. Moreover, transgene expression was more widely distributed and intensive in injured tendons. Without being bound by theory, this observation is most likely due to an increased cell number and a raised metabolic activity in injured tendons as compared to intact tendon. Another possible explanation, but again without being bound by theory, could be the circumstance that parts of the extracellular matrix were disintegrated in injured tendons and as a consequence, connections between fibers were loosened. Indeed injected cmRNA may spread more widely between fibers and therefore reached a larger number of cells.

**[0099]** With respect to biological compatibility, intact tendons were examined histopathologically 24 hours after injection of cmRNA<sup>LUC</sup>. The examination showed only a mild unspecific inflammatory reaction near the injection site. It can't be excluded that the cmRNA itself, the expressed protein, mechanical stress due to volume injection, or trauma caused by needle insertion, induced a mild unspecific local immune response, however. Liver and kidney test values as well as full blood count were conducted to investigate cmRNA's pharmaceutical safety in large animals after local application into tendons. In our short term studies mRNA did

not lead to organ damage in liver or kidney and did not relevantly affect the immune system as determined values remained within the physiological range 24 hours after cmRNA application or have already slightly differed beforehand. It is readily possible to evaluate mRNA's therapeutic potential in chemically disintegrated tendons by application of cmRNA encoding for therapeutic proteins in an established defect model with partial failure as, for example, disclosed herein.

[0100] These results indicate that cmRNAs has the potential as a novel pro-drug, which could be used for expressing therapeutic proteins in injured tendons. Further long-term investigations can be made on the therapeutic potential, of, for example, BMP-7, for the treatment of tendon disorders.

[0101] The present invention refers to the following supplemental Tables:

**Table 2**

**Solutions used for cmRNA dilution. A selection of primary ingredients is listed.**

<sup>1</sup> commercially available, <sup>2</sup> standard chemical solutions made in-house, HEPES: 2-(4-(2-hydroxyethyl)-1-piperazinethansulfonic acid.

Description	Label	Primary Ingredients
Nitrogen compound containing	Ammonium acetate solution <sup>1</sup> Aminosteril plus <sup>1</sup>	Ammonium acetate Total aminoacids 100g/l, K, Ca, Mg, Cl, Phosphate, Acetate
	Aminoven 15% <sup>1</sup>	Total aminoacids 150g/l
Colloidal solutions	HAES steril 10% <sup>1</sup>	Hydroxyethyl starch 100g/l, Na, Cl
	Gelafundin 4% <sup>1</sup>	Gelatine polysuccinate 40g/l, Na, Cl
Glucose containing	HEPES buffered glucose 2,5% <sup>2</sup>	12,5mM HEPES, Glucose 25g/l
	HEPES buffered glucose 3,75% <sup>2</sup>	18,75mM HEPES, Glucose 37,5g/l
	HEPES buffered glucose 5% <sup>2</sup>	25mM HEPES, Glucose 50g/l
	HEPES buffered glucose 10% <sup>2</sup>	50mM HEPES, Glucose 100g/l
Elektrolyte containing	Isotonic saline (NaCl) <sup>2</sup>	Glucose, Na, Cl
	Ringer acetate <sup>1</sup>	Na, K, Ca, Mg, Cl, Acetate
	Ringer lactate <sup>1</sup>	Na, K, Ca, Cl, Lactate
Elektrolyte and glucose containing	Isotonic saline + 5% glucose <sup>2</sup> (NaCl+5%Gluc)	Glucose 50g/l, Na, Cl

n=2, \*n=1). Reference ranges: <sup>1</sup> 4-10 postprandial < 40 µmol/l, <sup>11</sup> <

d 7  
4.2 ±0.7  
36.0 ±0.0  
564 ±43  
7.5 ±2.1  
0.7 ±0.1  
89 ±63  
92 ± 35

**Table 3**

**Analysis of blood count and organ test values.** Results are presented as the mean  $\pm$  SD (11 G/l, <sup>2</sup> 27-40%, <sup>3</sup> 280-650 G/l, <sup>4</sup> 5-11 mg/dl, <sup>5</sup> < 1.9 mg/dl, <sup>6,7</sup> < 180 U/l, <sup>8</sup> < 32 U/l, <sup>9</sup> < 9 U/l, 0.4 mg/dl, <sup>12</sup> 2-3 g/dl.

68	61	73	78	65 $\pm$ 1	63	59	57
$\pm$ 5.7	$\pm$ 5.7	$\pm$ 11	$\pm$ 21	$\pm$ 6.4	$\pm$ 4.2	$\pm$ 3.5	$\pm$ 3.5
4.5	7	6	3.5	3	6.5	6.5	6.5
$\pm$ 2.1	$\pm$ 4.2	$\pm$ 1.4	$\pm$ 0.7	$\pm$ 0.0	$\pm$ 0.7	$\pm$ 3.5	$\pm$ 3.5
8.6	12.4	12	2.7	10.4	4.5	4.6	26.6
$\pm$ 10.5	$\pm$ 6.9	$\pm$ 9.5	$\pm$ 1.8	$\pm$ 7.6	$\pm$ 3.5	$\pm$ 4.2	$\pm$ 26.4
0.3	0.4	0.2	0.35	0.2	0.3	0.25	0.2
$\pm$ 0.1	$\pm$ 0.0	$\pm$ 0.0	$\pm$ 0.1	$\pm$ 0.0	$\pm$ 0.1	$\pm$ 0.1	$\pm$ 0.0
3.7	3.5	3.7	3.8	3.2	3.1	2.9	2.9
$\pm$ 0.4	$\pm$ 0.2	$\pm$ 0.5	$\pm$ 0.8	$\pm$ 0.1	$\pm$ 0.3	$\pm$ 0.3	$\pm$ 0.2

	amount of cmRNA			400 $\mu$ g			800 $\mu$ g			1000 $\mu$ g		
	d0	d6	d7	d0	d6	d7	d0	d6	d7	d0	d6	d7
<b>WBC [G/l]<sup>1</sup></b>	7.4	6.2	7.6*	6.8*	5.2	6.1	4.2	3.6	$\pm$ 0.2	$\pm$ 0.2	$\pm$ 0.1	$\pm$ 0.1
<b>HCT [%]<sup>2</sup></b>	48.3	51.7	43.9*	41.5	35.5	40.0	29.5	29.0	$\pm$ 0.7	$\pm$ 2.1	$\pm$ 1.4	$\pm$ 6.4
<b>PLT [G/L]<sup>3</sup></b>	409*	500	461*	450	554 $\pm$	562	521	421	$\pm$ 87	$\pm$ 152	$\pm$ 172	$\pm$ 52
<b>blood urea nitrogen [mg/dl]<sup>4</sup></b>	21*	11	7.5	17	13.5	6	14	12	$\pm$ 0.0	$\pm$ 0.7	$\pm$ 4.2	$\pm$ 3.5
<b>Creatinine [mg/dl]<sup>5</sup></b>	1.1*	1.0	1.1	1.1	1.2	1.1	0.8	0.7	$\pm$ 0.0	$\pm$ 0.1	$\pm$ 0.1	$\pm$ 0.1
<b>alkaline phos- phatase (AP) [U/l]<sup>6</sup></b>	79*	61 $\pm$ 5	49 $\pm$ 9	102	88	89	69	74	$\pm$ 38	$\pm$ 34	$\pm$ 47	$\pm$ 21
<b>aspartate aminotransferase (AST) [U/l]<sup>7</sup></b>	109*	161	152	99	177	139	81	78 $\pm$	$\pm$ 23	$\pm$ 21	$\pm$ 10	$\pm$ 6

$\gamma$ -glutamyltrans-ferase ( $\gamma$ -GT) [U/l] <sup>8</sup>	75*
glutamate dehydrogenase (GLDH) [U/l] <sup>9</sup>	3*
bile acids [ $\mu$ mol/l] <sup>10</sup>	4.3*
total bilirubin [mg/dl] <sup>11</sup>	0.3*
serum albumin [g/dl] <sup>12</sup>	3.8*

[0102] The present invention refers to the following nucleotide sequences:

SEQ ID NO. 1:

Nucleotide sequence encoding *Homo sapiens* bone morphogenetic protein 7 (BMP7)

Pubmed accession number: NM\_001719

Version: NM\_001719.2 GI:187608319

AGCGCGTACCACTCTGGCGCTCCCAGAGCGGCCCTCTTGTGCGATCCAGGGCGCACAAAGGCTGGGAGAGCGCCCCG  
GGGCCCCCTGCTATCCGCGCCGGAGGTTGGAAGAGGGTGGGTTGCCGCCGCCGAGGGCGAGAGCGCCAGAGGAGC  
GGGAAGAAGGAGCGCTCGCCCGCCCGCCTGCCTCCTCGCTGCCTCCCCGGCGTTGGCTCTCTGGACTCCTAGGCT  
TGCTGGCTGCTCCTCCCACCCGCGCCCGCCTCCTCACTCGCCTTTTCGTTCCGCCGGGGCTGCTTCCAAGCCCTG  
CGGTGCGCCCCGGGCGAGTGCGGGGCGAGGGGCCCGGGGCCAGCACCAGCAGGGGGCGGGGGTCCGGGCAGAGCG  
CGGCCGCGCCGGGAGGGGCCATGTCTGGCGCGGGCGCAGCGGGGCCCGTCTGCAGCAAGTGACCGAGCGGCGCGG  
ACGGCCGCTGCCCCCTCTGCCACCTGGGGCGGTGCGGGCCCGGAGCCCGGAGCCCGGGTAGCGGTAGAGCCGG  
CGCGATGCACGTGCGCTCACTGCGAGCTGCGGCGCGCACAGCTTCGTGGCGCTCTGGGCACCCCTGTTCCCTGCT  
GCGTCCGCCCTGGCCGACTTCAGCCTGGACAACGAGGTGCACTCGAGCTTCATCCACCGGCGCCTCCGCAGCCA  
GGAGCGGCGGGAGATGCAGCGGAGATCCTCTCCATTTTGGGCTTGCCCCACCGCCGCGCCCGCACCTCCAGGG  
CAAGCACAACCTCGGCACCCATGTTTCATGCTGGACCTGTACAACGCCATGGCGGTGGAGGAGGGCGGGCGGGCCCGG  
CGGCCAGGGCTTCTCCTACCCCTACAAGGCCGTCTTCAGTACCCAGGGCCCCCTCTGGCCAGCCTGCAAGATAG  
CCATTTCCCTCACCAGCGCCGACATGGTCATGAGCTTCGTCAACCTCGTGGAACATGACAAGGAATTCCTCCACCC  
ACGCTACCACCATCGAGAGTTCGGTTTGATCTTTCCAAGATCCCAGAAGGGGAAGCTGTCACGGCAGCCGAATT  
CCGGATCTACAAGACTACATCCGGGAACGCTTCGACAATGAGACGTTCCGGATCAGCGTTTATCAGGTGCTCCA  
GGAGCACTTGGGCAGGGAATCGGATCTTCTCTGCTCGACAGCCGTACCCTCTGGGCCTCGGAGGAGGGCTGGCT  
GGTGTGACATCACAGCCACCAGCAACCACTGGGTGGTCAATCCCGGCACAACCTGGGCCTGCAGCTCTCGGT  
GGAGACGCTGGATGGGCAGAGCATCAACCCCAAGTTGGCGGGCCTGATTGGGCGGCACGGGCCCCAGAACAAGCA  
GCCCTTCATGGTGGCTTTCTTCAAGGCCACGGAGTCCACTTCCGCAGCATCCGGTCCACGGGGAGCAAACAGCG  
CAGCCAGAACCGCTCCAAGACGCCAAGAACCAGGAAGCCCTGCGGATGGCCAACGTGGCAGAGAACAGCAGCAG  
CGACCAGAGGCAGGCCTGTAAGAAGCACGAGCTGTATGTCAGCTTCCGAGACCTGGGCTGGCAGGACTGGATCAT  
CGCGCCTGAAGGCTACGCCGCTACTACTGTGAGGGGGAGTGTGCCTTCCTCTGAACTCCTACATGAACGCCAC  
CAACCACGCCATCGTGCAGACGCTGGTCCACTTCATCAACCCGGAACGTTGCCAAGCCCTGCTGTGCGCCAC  
GCAGCTCAATGCCATCTCCGTCTTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACAGAAACATGGT  
GGTCCCGGCCCTGTGGCTGCCACTAGCTCCTCCGAGAATTCAGACCCCTTTGGGGCCAAGTTTTTCTGGATCCTCCA  
TTGCTCGCCTTGGCCAGGAACCAGCAGACCAACTGCCTTTTGTGAGACCTTCCCCTCCCTATCCCCAACTTTAAA  
GGTGTGAGAGTATTAGGAAACATGAGCAGCATATGGCTTTTGTATCAGTTTTTTCAGTGGCAGCATCCAATGAACAA  
GATCCTACAAGCTGTGCAGGCAAAACCTAGCAGGAAAAAACAACGCATAAAGAAAAATGGCCGGGCCAGGTC  
ATTGGCTGGGAAGTCTCAGCCATGCACGACTCGTTTTCCAGAGGTAATTATGAGCGCCTACCAGCCAGGCCACCC  
AGCCGTGGGAGGAAGGGGGCGTGGCAAGGGGTGGGCACATTGGTGTCTGTGCGAAAGGAAAATTGACCCGGAAGT  
TCCTGTAATAAATGTCACAATAAAACGAATGAATGAAAATGGTTAGGACGTTACAGATATATTTTCTAAACAAT  
TTATCCCCATTTCTCGGTTTATCCTGATGCGTAAACAGAAGCTGTGTCAAGTGGAGGGCGGGGAGGTCCCTCTCC  
ATTCCCTACAGTTTTTCATCCTGAGGCTTGCAGAGGCCAGTGTTCACCGAGGTTTGCCCAAATCCAAGATCTAGT  
GGGAGGGGAAAGAGCAAATGTCTGCTCCGAGGAGGGCGGTGTGTTGATCTTTGGAGGAAAAATATGTTCTGTTGT  
TCAGCTGGATTTGCCGTGGCAGAAATGAACTAGGTGTGTGAAATACCCGACAGACATTTGGGATTGGCTTTTAC  
CTCGCCCCAGTGGTAGTAATCCATGTGAAATTGCAGAGGGGACAAGGACAGCAAGTAGGATGGAACCTGCAACT  
CAACCTGTTGTTAAGAAGCACAATGGGCCGGGCACAGTAGCTCCACCTGTAATCCCAGCACTTTGGGAGGCT  
GAGGTGGGCGGATCATTGAGGTGAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAA  
AATACAAAAATTAGCCGGGCATGGTGGCACGCACCTGTAATCCCAGCTACTCTGGAGGCTGAGGCAGGAGAATTG  
CTTGAACCCAGAGGTGGAGGTTGCAGTGAGCCAAGATCGTCCCACTGCACTCCAGCTTGGGTGACAAAACAAGA

CTCCATCTCAAAGAAAAAACAAGCAGCACCATGAAGCCTAGTTCTCCACGGGAGTGGGGTGAGCAGGAGCACT  
GCACATCGCCCCAGTGGACCCTCTGGTCTTTGTCTGCAGTGGCATTCCAAGGCTGGGCCCTGGCAAGGGCACCCG  
TGGCTGTCTCTTCATTTGCAGACCCTGATCAGAAGTCTCTGCAAACAAATTTGCTCCTTGAATTAAGGGGAGAT  
GGCATAATAGGAGGTCTGATGGGTGCAGGATGTGCTGGACTTACATTGCAAATAGAAGCCTTGTGAGGGTGACA  
TCCTAACCAAGTGTCCCGATTTGGAGGTGGCATTCTGACGTGGCTCTTGGTGTAAAGCCTGCCTTGCTTGGCTG

GTGAGTCCCATAAATAGTATGCACTCAGCCTCCGGCCACAAACACAAGGCCTAGGGGAGGGCTAGACTGTCTGCA  
AACGTTTTCTGCATCTGTAAAGAAAACAAGGTGATCGAAAACCTGTGGCCATGTGGAACCCGGTCTTGTGGGGAC  
TGTTTCTCCATCTTGAATCAGACAGTTCCTGGAAACACCGGGGCTCTGTTTTATTTCTTTGATGTTTTCTTC  
TTTAGTAGCTTGGGCTGCAGCCTCCACTCTCTAGTCACTGGGGAGGAGTATTTTTGTTATGTTTGGTTTCATTT  
GCTGGCAGAGCTGGGGCTTTTTGTGTGATCCCTCTTGGTGTGAGTTTTCTGACCCAACCAGCCTCTGGTTAGCAT  
CATTTGTACATTTAAACCTGTAAATAGTTGTTACAAAGCAAAGAGATTATTTATTTCCATCCAAAGCTCTTTGA  
ACACCCCCCCCCCTTAAATCCCTCGTTCAGGACGATGAGCTTGCTTTCCCTCAACCTGTTTGTCTTTCTATTAA  
GACTATTTATTAATGGTTGGACCAATGTAATCACAGCTGTTGCGTTCGAGCAGTCTTAGTGAAAATTCGTATAA  
ATAGACAAAATGAAAAGGGTTGACCTGCAATAAAAGGAGACGTTTGGTCTGGCAAAAAAAAAAAAAAAAAA

**[0103] ORF (underlined) from the above sequence may be codon optimized (e.g. by Eurofins).  
SEQ ID NO. 2:**

**Codon optimized mRNA sequence (DNA Format) resulting from the above SEQ ID  
NO. 1**

GGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCATGCACGTACGCAGTCTTAGGGCTGC  
TGCCCCACACAGCTTTGTGGCCCTGTGGGCACCCCTCTTTCTGCTTAGGTCTGCTCTTGCCGACTTTTCACTGGA  
CAACGAGGTCCATTCCCTCATTTATCCACCGTTCGACTGAGAAGCCAAAGAGAGGGCGGAAATGCAGCGGAGATTTT  
GTCTATCCTGGGATTTGCCCATAGACCTCGTCCCATCTCCAAGGGAAACACAACCTCTGCTCCCATGTTGATGCT  
GGATCTGTACAATGCCATGGCAGTGGAGGAAGGTGGTGGCCAGGAGGACAGGGCTTCTCCTATCCGTACAAGGC  
CGTCTTTTCCACCAAGGTCCACCGTTGGCGAGTCTCCAGGATTTCCATTTCTGACCGATGCGGACATGTTGAT  
GTCATTGCTGAACCTGGTGGAAACACGACAAAGAGTTCTTTCACCCAGGTATCACCACAGAGAGTTCCGCTTCGA  
CTTGAGTAAAATCCCTGAGGGAGAAGCCGTTACTGCCGCGAGTTTCGCATTTACAAGGACTACATTCGGGAGAG  
GTTTCGATAACGAAACCTTCCGGATATCCGTGTATCAGGTGCTGCAAGAGCATCTGGGGAGAGAGTCCGATCTCTT  
CCTCCTGGACAGTAGGACACTGTGGGCTCTGAGGAAGGCTGGCTTGTGTTTCGACATAACTGCCACGAGCAATCA  
CTGGGTGTAAACCAAGGCATAACCTGGGGCTTCAGCTGTCTGTGAGACACTGGATGGGCAGAGCATCAATCC  
CAAACCTGGCTGGTGTGATCGGACGCCATGGTCCACAGAACAACAGCCTTTCATGGTAGCTTTCTTTAAGGCCAC  
AGAAGTGCATTTTCGGAGTATTCGGAGCACTGGCAGCAAACAGAGAAGCCAGAATAGATCCAAGACCCCTAAGAA  
TCAGGAAGCCCTGCGGATGGCAAATGTGGCGGAGAATAGCAGCTCAGATCAGAGACAGGCTTGCAAGAAGCATGA  
ACTGTATGTGCTTTTTCGAGATCTCGGATGGCAGGACTGGATTATCGCACCAGAGGGGCTATGCTGCCTACTATTG  
CGAAGGCGAGTGCATTTCTCTGAACAGCTACATGAACGCAACCAATCATGCCATTGTCCAACACTCGTTCA  
CTTCATCAATCCCGAAACTGTGCTAAACCTGTTGTGCACCTACGCAGCTGAACGCTATATCTGTTCTGTACTT  
TGACGATTCATCCAACGTCATCCTCAAGAAGTACCGCAATATGGTTGTCCGAGCATGCGGCTGTCACTGAGAATTC  
CTGCAGAAA  
AAAGCGGCC

**[0104] Large capital letters represent the BMP-7 ORF.  
SEQ ID NO. 3:**

**cmRNA sequence (RNA Format) resulting from the above SEQ ID NO. 1**

GGGAGACCCAAGCUGGCUAGCGUUUAAACUUAAGCUUGGUACCGAGCUCGGAUCCAUAGCAGUACGCAGUCUUAGGGCUGC  
UGCCCCACACAGCUUUGUGGCCUGUGGGCACCCUCUUUCUGCUUAGGUCUGCUCUUGCCGACUUUUCACUGGA  
CAACGAGGUCCAUUCUUAUUAUCCACCGUCGACUGAGAAGCCAAAGAGAGGGCGGAAAUGCAGCGGAGAUUUU  
GUCUAUCCUGGGAUUGCCCCAUAGACCUCGUCCCCAUCUCCAAGGGAAACACAACUCUGCUCCCAUGUUCAUGCU  
GGAUCUGUACAAUGCCAUGGCAGUGGAGGAAGGUGGUGGCCAGGAGGACAGGGCUUCUCCUAUCCGUACAAGGC  
CGUCUUUCCACCCAAGGUCCACCGUUGGCGAGUCUCCAGGAUUCCAUUUCUGACCGAUGCGGACAUGGUGAU

GUCAUUCGJGAACCUUGGUGGAACACGACAAAGAGUUCUUUCACCCAGGUUAUCACCACAGAGAGUUCGCUUCGA  
CUUGAGUAAAAUCCUGAGGGAGAAGCCGUUACUGCCGCGAGUUUCGCAUUUACAAGGACUACAUUCGGGAGAG  
GUUCGAUAACGAAACCUCCGGUAUUCGUGUAUCAGGUGCUGCAAGAGCAUCUGGGGAGAGAGUCCGAUCUCUU  
CCUCCUGGACAGUAGGACACUGUGGGCGUCUGAGGAAGGCUUGUGUUCGACAUAAUCGCCACGAGCAAUCA  
CUGGGUUGUAAACCAAGGCAUAACCUUGGGGCUUCAGCUGUCUGUCGAGACACUGGAUGGGCAGAGCAUCAUCC  
CAAACUGGCUGGGUUGAUCGGACGCCAUGGUCCACAGAACAACAGCCUUUCAUGGUAGCUUUUUAAGGCCAC  
AGAAGUGCACUUUCGGAGUAUUCGGAGCACUGGCAGCAAACAGAGAAGCCAGAAUAGAUCCAAGACCCCUAAGAA

UCAGGAAGCCCUGCGGAUGGCAAAUGUGGGCGGAGAAUAGCAGCUCAGAUCAAGAGACAGGCUUGCAAGAAGCAUGA  
 ACUGUAUGUGUCUUUUCGAGAUCUCGGAUGGCAGGACUGGAUUUUCGCACCAGAGGGCUAUGCUGCCUACUAAUUG  
 CGAAGGCGAGUGCGCAUUUCCUCUGAACAGCUACAUGAACGCAACCAUCAUGCCAUGUCCAAACACUCGUUCA  
 CUUCAUCAAUCCGGAAACUGUGCCUAAAACCCUGUUGUGCACCUCACGAGCUGAACGCUAUAUCUGUUCUGUACUU  
 UGACGAUUCAUCCAACGUCAUCCUCAAGAAGUACCGCAAUAUGGUUGUCCGAGCAUGCGGCUGUCACUGAGAAUUC  
 CUGCAGAAA  
 AAGCGGCC

[0105] Large capital letters represent the BMP-7 ORF.

**SEQUENCE LISTING**

[0106]

<110> ethris GmbH

<120> Use of RNA in the treatment of ligament or tendon lesions

<130> U3124 PCT S3

<150> EP14 17 7302.8

<151> 2014-07-16

<160> 3

<170> BiSSAP 1.3

<210> 1

<211> 4049

<212> DNA

<213> Homo sapiens

<400> 1

agcgcgtacc actctggcgc tcccgaggcg gcctcttgtg cgatccaggg cgcacaaggg	60
tgggagagcg ccccggggcc cctgctatcc gcgccggagg ttggaagagg gtgggttgcc	120
gccgcccagag ggcgagagcg ccagaggagc gggaagaagg agcgctcgcc cgcccgcctg	180
cctcctcgct gcctccccgg cgttggctct ctggactcct aggcttgtg gctgctcctc	240
ccacccgcgc ccgcctcctc actcgccttt tcgttcgceg gggctgcttt ccaagcctg	300
cggtgcgccc gggcgagtgc ggggagagg gcccggggcc agcaccgagc agggggcggg	360
ggtccgggca gagcgcggcc ggccggggag gggccatgtc tggcgcgggc gcagcggggc	420
ccgtctgcag caagtgaccg agcggcgcgg acggccgcct gcccctctg ccacctgggg	480
cggtgcgggc ccggagcccg gagcccgggt agcgcgtaga gccggcgcga tgcacgtgcg	540
ctcactgcga gctgcggcgc cgcacagctt cgtggcgcctc tgggcacccc tgttctgct	600
gcgctccgcc ctggccgact tcagcctgga caacgaggtg cactcgagct tcatccaccg	660
gcgcctccgc agccaggagc ggcgggagat gcagcgcgag atcctctcca ttttgggctt	720

gccccaccgc ccgcgcccgc acctccaggg caagcacaac tcggcaccca tgttcatgct 780  
ggacctgtac aacgccatgg cgggtggagga gggcggcggg cccggcggcc agggcttctc 840  
ctacccttac aaggccgtct tcagtaccca gggccccct ctggccagcc tgcaagatag 900  
ccatttcctc accgacgccg acatggtcat gagcttcgtc aacctcgtgg aacatgacaa 960  
ggaattcttc caccacgct accaccatcg agagttccgg tttgatcttt ccaagatccc 1020  
agaaggggaa gctgtcacgg cagccgaatt ccggatctac aaggactaca tccgggaacg 1080  
cttcgacaat gagacgttcc ggatcagcgt ttatcaggtg ctccaggagc acttgggcag 1140  
ggaatcggat ctcttcctgc tcgacagccg taccctctgg gcctcggagg agggctggct 1200  
ggtgtttgac atcacagcca ccagcaacca ctgggtggtc aatccgcggc acaacctggg 1260  
  
cctgcagctc tcggtggaga cgtggatgg gcagagcatc aacccaagt tggcgggct 1320  
gattgggcgg cacgggcccc agaacaagca gcccttcattg gtggctttct tcaaggccac 1380  
ggaggtccac ttccgcagca tccgggtccac ggggagcaaa cagcgcagcc agaaccgctc 1440  
caagacgccc aagaaccagg aagccctgcg gatggccaac gtggcagaga acagcagcag 1500  
cgaccagagg caggcctgta agaagcacga gctgtatgtc agcttccgag acctgggctg 1560  
gcaggactgg atcatcgcg ctgaaggcta cggcgcctac tactgtgagg gggagtgtgc 1620  
cttccctctg aactcctaca tgaacgccac caaccagcc atcgtgcaga cgctgggtcca 1680  
cttcatcaac ccggaaacgg tgcccaagcc ctgctgtgcg cccacgcagc tcaatgccat 1740  
ctccgtcctc tacttcgatg acagctccaa cgtcatcctg aagaaatata gaaacatggt 1800  
ggtccgggcc tgtggctgcc actagctcct ccgagaattc agacccttg gggccaagtt 1860  
tttctggatc ctccattgct cgccttggcc aggaaccagc agaccaactg ccttttgtga 1920  
gaccttcccc tcctatccc caactttaaa ggtgtgagag tattaggaaa catgagcagc 1980  
atatggcttt tgatcagttt ttcagtggca gcatccaatg aacaagatcc tacaagctgt 2040  
gcaggcaaaa cctagcagga aaaaaaaca acgcataaag aaaaatggcc gggccaggtc 2100  
attggctggg aagtctcagc catgcacgga ctcgtttcca gaggtaatta tgagcgccta 2160  
ccagccaggc caccagccg tgggaggaag gggcgtggc aaggggtggg cacattggtg 2220  
tctgtcgaa aggaaaattg acccggaagt tcctgtaata aatgtcacia taaaacgaat 2280  
gaatgaaaat ggttaggacg ttacagatat attttctaa acaatttatc cccatttctc 2340  
ggtttatcct gatgcgtaaa cagaagctgt gtcaagtgga gggcggggag gtccctctcc 2400  
attccctaca gtttcatcc tgaggcttgc agaggcccag tgtttaccga ggtttgcca 2460  
aatccaagat ctagtgggag gggaaagagc aatgtctgc tccgaggagg gcggtgtgtt 2520  
gatctttgga ggaaaaatat gttctgttgt tcagctggat ttgccgtggc agaaatgaaa 2580  
ctaggtgtgt gaaataccg cagacatttg ggattggctt ttcacctgc cccagtggta 2640  
gtaaatccat gtgaaattgc agaggggaca aggacagcaa gtaggatgga acttgcaact 2700  
caaccctggt gtaagaagc accaatgggc cgggcacagt agctcccacc tgtaatccca 2760  
gcactttggg aggctgaggt gggcggatca tttgaggtca ggagttcgag accagcctgg 2820  
ccaacatggt gaaacccat ctctactaaa aatacaaaa ttagccgggc atggtggcac 2880  
gcacctgtaa tcccagctac tctggaggct gaggcaggag aattgcttga accccagagg 2940  
tcaagttac atcaaccaa atcctccca ctacactcca ccttaaatca caaaacaara 3000

```

-----
ctccatctca aaagaaaaa aaaacagcac caatgaagcc tagttctcca cgggagtggg      3060
gtgagcagga gcactgcaca tcgccccagt ggaccctctg gtctttgtct gcagtggcat      3120
tccaaggctg ggccctggca agggcaccog tggtgtctc ttcatttgca gaccctgatc      3180

agaagtctct gcaaacaat ttgctccttg aattaagggg gagatggcat aataggaggt      3240
ctgatgggtg caggatgtgc tggacttaca ttgcaaatag aagccttgtt gagggtgaca      3300
tcctaaccaa gtgtcccgat ttggaggtgg catttctgac gtggctcttg gtgtaagcct      3360
gccttgccct ggctgggtgag tcccataaat agtatgcact cagcctccgg ccacaaacac      3420
aaggcctagg ggagggctag actgtctgca aacgttttct gcatctgtaa agaaaacaag      3480
gtgatcgaaa actgtggcca tgtggaacct ggtcttgtgg gggactgttt ctccatcttg      3540
actcagacag ttccctggaaa caccggggct ctgtttttat tttctttgat gtttttcttc      3600
tttagtagct tgggctgcag cctccactct ctagtcaactg gggaggagta ttttttgta      3660
tgtttggttt catttgctgg cagagctggg gctttttgtg tgatecctct tgggtgtgagt      3720
ttctgacce aaccagcctc tggttagcat catttgtaaa tttaaacctg taaatagttg      3780
ttacaaagca aagagattat ttatttccat ccaaagctct tttgaacacc cccccctt      3840
taatccctcg ttcaggacga tgagcttgc ttccttcaac ctgtttggtt tcttatttaa      3900
gactatttat taatggttgg accaatgtac tcacagctgt tgcgtcgagc agtccttagt      3960
gaaaattctg tataaataga caaaatgaaa agggtttgac cttgcaataa aaggagacgt      4020
ttggttctgg caaaaaaaaa aaaaaaaaaa      4049

```

<210> 2

<211> 1489

<212> DNA

<213> Artificial Sequence

<220>

<223> codon optimized mRNA sequence (DNA format) encoding BMP-7

<400> 2

```

gggagaccca agctggctag cgtttaaact taagcttggg accgagctcg gatccatgca      60
cgtaocgca cttagggctg ctgccccaca cagctttgtg gccctgtggg caccctctt      120
tctgcttagg tctgctcttg ccgacttttc actggacaac gaggtccatt cctcatttat      180
ccaccgtcga ctgagaagcc aagagaggcg ggaaatgcag cgcgagattt tgtctatcct      240
gggattgccc catagacctc gtccccatct ccaagggaaa cacaactctg ctcccatgtt      300
catgctggat ctgtacaatg ccatggcagt ggaggaaggt ggtggcccag gaggacaggg      360
cttctcctat ccgtacaagg ccgtcttttc cacccaaggt ccaccgttgg cgagtctcca      420
ggattcccat ttccctgaccg atgcggacat ggtgatgtca ttcgtgaacc tgggtggaaca      480
cgacaaagag ttctttcacc ccaggtatca ccacagagag ttccgcttcg acttgagtaa      540
aatccctgag ggagaagccg ttactgccgc cgagtttcgc atttacaagg actacattcg      600
ggagaggttc gataacgaaa ccttccggat atccgtgtat caggtgctgc aagagcatct      660

```

ggggagagag tccgatctct tcctcctgga cagtaggaca ctgtgggcgt ctgaggaagg 720  
 ctggcttgtg ttcgacataa ctgccacgag caatcactgg gttgtaaacc caaggcataa 780  
 cctggggcctt cagctgtctg tcgagacact ggatgggcag agcatcaatc ccaaactggc 840  
 tgggttgatc ggacgccatg gtccacagaa caaacagcct ttcattgtag ctttctttaa 900  
 ggccacagaa gtgcactttc ggagtattcg gagcactggc agcaaacaga gaagccagaa 960  
 tagatccaag acccctaaga atcaggaagc cctgcggatg gcaaatgtgg cggagaatag 1020  
 cagctcagat cagagacagg cttgcaagaa gcatgaactg tatgtgtctt ttcgagatct 1080  
 cggatggcag gactggatta tcgcaccaga gggctatgct gcctactatt gcgaaggcga 1140  
 gtgcgcatth cctctgaaca gctacatgaa cgcaaccaat catgccattg tccaaacact 1200  
 cgttcacttc atcaatccgg aaactgtgcc taaaccctgt tgtgcaccta cgcagctgaa 1260  
 cgctatatct gttctgtact ttgacgattc atccaacgtc atcctcaaga agtaccgcaa 1320  
 tatggttgtc cgagcatgcg gctgtcactg agaattcctg cagaaaaaaaa aaaaaaaaaa 1380  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1440  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagcggcc 1489

<210> 3

<211> 1489

<212> RNA

<213> Artificial Sequence

<220>

<223> codon optimized mRNA sequence (RNA format) encoding BMP-7

<400> 3

gggagaccca agcuggcuag cguuuuaacu uaagcuuggu accgagcucg gauccaugca 60  
 cguacgcagu cuuagggcug cugccccaca cagcuuugug gccuguggg caccucucu 120  
 ucugcuuagg ucugcucuug ccgacuuuuc acuggacaac gagguccauu ccucauuuau 180  
 ccaccgucga cugagaagcc aagagaggcg ggaaaugcag cgcgagauuu ugucuauccu 240  
 gggauugccc cauagaccuc guccccaucu ccaagggaaa cacaacucug cucccauguu 300  
 caugcuggau cuguacaaug ccauggcagu ggaggaaggu gguggcccag gaggacaggg 360  
 cuucuccuau ccguacaagg ccgucuuuuc cacccaaggu ccaccguugg cgagucucca 420  
 ggauucccau uuccugaccg augcggacau ggugauguca uucgugaacc ugguggaaca 480  
 cgacaaagag uucuuucacc ccagguauc ccaagagag uuccgcuucg acuugaguaa 540  
 aaucccugag ggagaagccg uuacugccgc cgaguuucgc auuuacaagg acuacauucg 600  
 ggagagguuc gauaacgaaa ccuuccggau auccguguau caggugcugc aagagcaucu 660  
 ggggagagag uccgaucucu uccuccugga caguaggaca cugugggcu cugaggaagg 720  
 cuggcuugug uucgacauaa cugccacgag caaucacugg guuguaaacc caaggcauaa 780  
 ccuggggcuu cagcugucug ucgagacacu ggaugggcag agcaucaauc ccaaacuggc 840  
 uggguugauc ggacgccaug guccacagaa caaacagccu uucaugguag cuuucuuuaa 900

```

ggccacagaa gugcacuuuc ggaguauucg gagcacuggc agcaaacaga gaagccagaa      960
uagauccaag accccuaaga aucaggaagc ccugcgggag gcaaaugugg cggagaaauag      1020
cagcucagau cagagacagg cuugcaagaa gcaugaacug uaugugucuu uucgagaucu      1080
cggauggcag gacuggauua ucgcaccaga gggcuaugcu gccuacuauu gcgaaggcga      1140
gugcgcauuu ccucugaaca gcuacaugaa cgcaaccaau caugccaauug uccaaacacu      1200
cguucacuuc aucaauccgg aaacugugcc uaaaccucgu ugugcaccua cgcagcugaa      1260
cgcuauaucu guucuguacu uugacgauuc auccaacguc auccucaaga aguaccgcaa      1320
uauugguugc cgagcaugcg gcugucacug agaauuccug cagaaaaaaaa aaaaaaaaaa      1380
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      1440
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagcggcc                    1489

```

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Patent documents cited in the description

- [WO2007103787A \[0002\]](#)
- [WO2017103787A \[0002\]](#)
- [WO2011012316A \[0025\] \[0030\] \[0032\] \[0046\] \[0046\] \[0048\] \[0049\]](#)
- [EP14177302A \[0106\]](#)

### Non-patent literature cited in the description

- FRANK, CBJ. Am. Acad. Orthop. Surgeons, 1996, vol. 4, 74-83 [\[0002\]](#)
- EVANSCH, Sports Med., 1999, vol. 28, 71-76 [\[0002\]](#) [\[0025\]](#)
- NAKAMURA et al. J. Clin. Invest., 1996, vol. 97, 226-231 [\[0002\]](#)
- NAKAMURA et al. Gene Therapy, 1998, vol. 5, 1165-1170 [\[0002\]](#)
- OZKAN et al. Eur. J. Clin. Invest., 1999, vol. 29, 63-67 [\[0002\]](#)
- GOOMER et al. Clinical Orthopaedics and Related Research, 2000, vol. 379S, S189-

S200 [0002]

- JAYANKURA et al. J. Gene Med., 2003, vol. 5, 618-624 [0002]
- Ultrasonics, 2010, vol. 50, 269-272 [0002]
- J. Controlled Release, 2011, vol. 156, 223-230 [0002]
- SUWALSKI et al. Biomaterials, 2010, vol. 31, 5237-5245 [0002]
- QUI et al. Gene Therapy, 2012, vol. 19, 703-710 [0002]
- RIBBANS Bone Joint J, 2013, vol. 95-B, 305-313 [0010]
- GOOD et al. Biochemistry, 1966, vol. 5, 467-477 [0018]
- GOOD et al. Methods Enzymol., 1972, vol. 24, 53-6 [0018]
- FERGUSON et al. Anal. Biochem., 1980, vol. 104, 300-310 [0018]
- BHAN AMANDAL SS Chem Med Chem., 2014, [0024]
- GUERQUIN et al. J. Clin. Invest., 2013, vol. 123, 3564-3576 [0025]
- HUANHUAN LIU et al. Cell and Tissue Research, 2014, vol. 356, 287-298 [0025]
- SAMBROOK, J. FRITSCH, E. F. MANIATIS, T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press 1989 0000 vol. 1, 2, 3, [0048]
- DAI et al. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2003, vol. 21, 604-9 [0065]
- WATTSE Equine veterinary journal, 2012, vol. 44, 576-86 [0072] [0091] [0097]
- SMITHE Equine veterinary journal, 2014, vol. 46, 4-9 [0072]
- YEH Journal of cellular biochemistry, 2008, vol. 104, 2107-22 [0080] [0096]
- PAULY Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons, 2012, vol. 21, 464-73 [0080]
- KVIST Sports medicine, 1994, vol. 18, 173-201 [0091] [0097]
- JARVINEN Foot and ankle clinics, 2005, vol. 10, 255-66 [0091]
- HERRMANN Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca, 2014, vol. 81, 256-66 [0091]
- PATTERSON-KANE IJAR journal / National Research Council Institute of Laboratory Animal Resources 2014 0000 vol. 55, 86-99 [0091]
- PERKINS New Zealand veterinary journal, 2005, vol. 53, 184-92 [0091]
- BAIRD Connective tissue research, 2014, vol. 55, 275-81 [0091]
- IPPOLITO Italian journal of orthopaedics and traumatology, 1975, vol. 1, 133-9 [0091]
- MAGNAN Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons, 2014, vol. 20, 154-9 [0091]
- JARVINEN Scandinavian journal of medicine & science in sports, 1997, vol. 7, 86-95 [0091]
- REEST The American journal of sports medicine, 2009, vol. 37, 1855-67 [0091]
- BRAY Journal of anatomy, 1996, vol. 188, 87-95 [0092]
- SHARMA Journal of musculoskeletal & neuronal interactions, 2006, vol. 6, 181-90 [0092] [0092]
- LIU Tissue engineering Part B, 2011, vol. 17, 165-76 [0092]
- JAMES The Journal of hand surgery, 2008, vol. 33, 102-12 [0092]
- WILLIAMS Sports medicine, 1986, vol. 3, 114-35 [0092]
- SHARMA Foot and ankle clinics, 2005, vol. 10, 383-97 [0092] [0095]
- HOGAN The Journal of the American Academy of Orthopaedic Surgeons, 2011, vol. 19,

- 134-42 [0092]
- **MAST**The Surgical clinics of North America, 1997, vol. 77, 529-47 [0092]
  - **MUTO**Journal of orthopaedic researchOrthopaedic Research Society20140000vol. 32, 1297-304 [0092]
  - **HART**Clinical journal of sport medicineCanadian Academy of Sport Medicine20110000vol. 21, 540-1 [0092]
  - **MUNETA**Journal of orthopaedic scienceJapanese Orthopaedic Association20120000vol. 17, 425-31 [0092]
  - **FOLAND**American journal of veterinary research, 1992, vol. 53, 2371-6 [0092]
  - **MORAES**The Veterinary record, 2009, vol. 165, 203-5 [0092]
  - **BOSCH**Equine veterinary journal, 2007, vol. 39, 226-31 [0092]
  - **SEELIGER**European journal of medical research, 2014, vol. 19, 37- [0092]
  - **SMITH**Disability and rehabilitation, 2008, vol. 30, 1752-8 [0092]
  - **MARTINELLO**Journal of orthopaedic researchOrthopaedic Research Society20130000vol. 31, 306-14 [0092]
  - **RENZI**Research in veterinary science, 2013, vol. 95, 272-7 [0092]
  - **WITTE**Journal of the American Veterinary Medical Association, 2011, vol. 239, 992-7 [0092]
  - **SHAH**Journal of orthopaedic researchOrthopaedic Research Society20130000vol. 31, 413-20 [0092]
  - **ARGUELLE**The Veterinary record, 2008, vol. 162, 208-11 [0092]
  - **DE VOS**British journal of sports medicine, 2011, vol. 45, 387-92 [0092]
  - **MOLLOY**Sports medicine, 2003, vol. 33, 381-94 [0092]
  - **EVANS**Sports medicine, 1999, vol. 28, 71-6 [0092]
  - **GROTENDORST**International journal of tissue reactions, 1988, vol. 10, 337-44 [0092]
  - **MAJEWSKI**Gene therapy, 2008, vol. 15, 1139-46 [0092] [0092]
  - **BOSCH**Journal of orthopaedic researchOrthopaedic Research Society20100000vol. 28, 211-7 [0092]
  - **NAKAMURA**Gene therapy, 1998, vol. 5, 1165-70 [0092]
  - **EVANS**International orthopaedics, 2014, [0092]
  - **LOU**Journal of orthopaedic researchOrthopaedic Research Society20010000vol. 19, 1199-202 [0092]
  - **TONG**Current gene therapy, 2009, vol. 9, 495-502 [0092]
  - **KORMANN**Nature biotechnology, 2011, vol. 29, 154-7 [0092] [0093]
  - **ZANGI**Nature biotechnology, 2013, vol. 31, 898-907 [0092] [0093]
  - **ELIASSON**Clinical orthopaedics and related research, 2008, vol. 466, 1592-7 [0094]
  - **YEE**Journal of orthopaedic researchOrthopaedic Research Society20110000vol. 29, 816-21 [0094] [0096]
  - **RUI**Knee surgery, sports traumatology, arthroscopyjournal of the ESSKA20120000vol. 20, 1409-17 [0094]
  - **YU**Arthroscopy: the journal of arthroscopic & related surgery: official publication of the Arthroscopy Association of North America and the International Arthroscopy Association20070000vol. 23, 205-10 [0094]
  - **LUI**BMC musculoskeletal disorders, 2013, vol. 14, 248- [0094]

- **SHARMA**The surgeon: journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 2005, vol. 3, 309-16 [\[0095\]](#)
- **LOISELLE**PloS one, 2012, vol. 7, e40602- [\[0095\]](#)
- **FORSLUND**Acta orthopaedica Scandinavica, 1998, vol. 69, 622-6 [\[0096\]](#)
- **LUI**Rheumatology, 2013, vol. 52, 2116-26 [\[0096\]](#)
- **JOZSA**ChampaignHuman Kinetics19970000 [\[0097\]](#)
- **RILEY**Matrix biologyInternational Society for Matrix Biology20020000vol. 21, 185-95 [\[0097\]](#)
- **PECINA**Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca, 2010, vol. 77, 277-83 [\[0097\]](#)
- **CASTAGNA**Muscles, ligaments and tendons journal, 2013, vol. 3, 132-8 [\[0097\]](#)
- **JONES**Arthritis and rheumatism, 2006, vol. 54, 832-42 [\[0097\]](#)
- **MUIR**Veterinary Surgery, 2005, vol. 34, 482-90 [\[0097\]](#)
- **NOMURAJ** Vet Med Sci., 2007, vol. 69, 637-9 [\[0097\]](#)
- **KANNUS**Scandinavian journal of medicine & science in sports, 1997, vol. 7, 78-85 [\[0097\]](#)

**Patentkrav**

- 1.** Flydende sammensætning indeholdende nøgent RNA til anvendelse til behandling eller forebyggelse af ledbånds- eller senelæsioner, hvor RNA'et er opløst i en glukoseopløsning, og hvor RNA'et er mRNA, og hvor polypeptidet kodet af mRNA'et er valgt fra gruppen bestående af blodpladeafledt vækstfaktor (PDGF), basisk fibroblastvækstfaktor (bFGF), insulin-lignende vækstfaktor 1(IGF-1), transformerende vækstfaktor  $\beta$ 1 (TGF- $\beta$ 1), epidermal vækstfaktor (EGF), en vækst- og differentieringsfaktor (GDF), Vegf og knoglemorfoenetisk protein (BMP).
- 10
- 2.** Sammensætningen til anvendelse ifølge krav 1, hvor polypeptidet er et polypeptid, som er terapeutisk aktivt i ledbånds- eller senehelingsprocessen.
- 3.** Sammensætningen til anvendelse ifølge krav 1 eller 2, hvor
- 15 glukoseopløsningen er en bufret glukoseopløsning.
- 4.** Sammensætningen til anvendelse ifølge krav 3, hvor den bufrede glukoseopløsning er en HEPES-bufret glukoseopløsning.
- 20 **5.** Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor koncentrationen af RNA'et i sammensætningen er mellem 0,1 til 5,0  $\mu$ g/ $\mu$ l.
- 6.** Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor sammensætningen indgives til ledbåndet eller senen via injektion.
- 25
- 7.** Sammensætningen til anvendelse ifølge krav 6, hvor injektionen udføres med en sprøjte med en nål, som har en diameter i området fra 20G til 27G.
- 8.** Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1 til 7,
- 30 hvor nævnte flydende sammensætning skal indgives før eller under den inflammatoriske fase, som følger nævnte ledbånds- eller senelæsioner.
- 9.** Terapeutisk sammensætning indeholdende RNA, hvor RNA'et er mRNA, som koder for et polypeptid, som er terapeutisk aktivt i ledbånds- eller senehelings-

processen valgt fra gruppen bestående af blodpladeafledt vækstfaktor (PDGF), basisk fibroblastvækstfaktor (bFGF), insulin-lignende vækstfaktor 1(IGF-1), transformerende vækstfaktor  $\beta$ 1 (TGF- $\beta$ 1), epidermal vækstfaktor (EGF), GDF'er, Vegf, og BMP, hvor sammensætningen er en glukoseopløsning indeholdende 5 mRNA'et i nøgen form.


**10.** Den terapeutiske sammensætning ifølge krav 9, hvor glukoseopløsningen er en bufret glukoseopløsning.

10 **11.** Den terapeutiske sammensætning ifølge krav 10, hvor den bufrede glukoseopløsning er en HEPES-bufret glukoseopløsning.

**12.** Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1 til 8 eller den terapeutiske sammensætning ifølge et hvilket som helst af kravene 9 til 15 11, hvor GDF'en er GDF 5, 6 (BMP-13), 7 (BMP-12), eller myostatin (GDF-8).

**13.** Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1 til 8 eller den terapeutiske sammensætning ifølge et hvilket som helst af kravene 9 til 11, hvor BMP'en er BMP-6 eller BMP-7.

## DRAWINGS






Figure 2




Figure 3




Figure 4








Figure 5

**Figure 6**

**Figure 7**



**Figure 9**




Figure 10a




Figure 10b



Figure 10c






Figure 10d




**Figure 11 A-B**




**Figure 11 C-D**


A.



B.



**Figure 12 A-B**



**Figure 13**




Figure 14




Figure 15




Figure 16




Figure 17






Figure 17 cont.



**Figure 18**





Figure 19



**Figure 20**